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ABSTRACT 
 
THE TRANSCRIPTIONAL EFFECTS OF PHOTOBIOMODULATION IN AN IN VITRO 
MODEL OF DIABETIC RETINOPATHY 
 
 
by 
Hannah Fisher 
 
The University of Wisconsin-Milwaukee, 2016 
Under the Supervision of Janis T. Eells, Ph.D 
 
 
Diabetic retinopathy (DR) is the most common complication of diabetes mellitus and a 
leading cause of blindness. The pathophysiology of DR is complicated, involving 
inflammation, oxidative stress, retinal vascular proliferation, and vascular degeneration. 
Symptomatically, the growth and subsequent rupture of vessels within the frame of view 
leads to the development of vision loss and eventual blindness.  Prior to the 
development of symptoms, oxidative stress involved in DR leads to the activation of the 
transcription factor, nuclear factor-B (NF-B), resulting in the excess production of 
vascular endothelial growth factor (VEGF) and intracellular adhesion molecule-1 (ICAM- 
1), proteins involved in vascular development and immune dysregulation, respectively. 
The most common therapeutic approach for DR utilizes anti-VEGF agents to reduce 
vascular proliferation. These treatments are expensive, invasive, frequently ineffective, 
and have numerous adverse effects, such as retinal detachment, infection, and 
inflammation inside the eye.  A non-invasive alternative therapy is clearly needed. 
Photobiomodulation (PBM) using far-red to near infrared (NIR) light has been shown to 
reduce oxidative stress and inflammation in vitro and in vivo and is an ideal candidate 
for an alternative therapy.  Indeed, PBM slows the progression of DR in animal models 
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via attenuation of oxidative stress and by reducing the relative level of ICAM-1. We 
hypothesize that PBM will reduce the activity of NF-B and reduce the production of 
VEGF and ICAM-1 in an in vitro model of DR. To test this hypothesis, we used an in 
vitro model system of cultured retinal Müller glial cells grown in normal (5 mM) or high 
(25 mM) glucose conditions for either 3 or 6 days to simulate normoglycemia and 
hyperglycemia. Cultures were treated with 670 nm light emitting diode (LED) (180 
seconds at 25 mW/cm2; 4.5 J/cm2) or no light (sham) for 3 or 5 days. NF-B activity and 
ICAM-1 concentrations were significantly increased under high glucose conditions, as 
measured by a dual luciferase assay or western blot, respectively. Treatment with 670 
nm LED significantly reduced NF-B activity of high glucose culture cells to values 
comparable to transcriptional activity measured under normoglycemic condition and 
decreased the level of ICAM-1. VEGF concentrations were not affected by high glucose 
or PBM. These data are in partial support of our central hypothesis that in an in vitro 
model of DR, 670 nm light will reduce activation of NF-B, and reduce the synthesis of 
ICAM-1 and VEGF.  The lack of an observable effect of hyperglycemia or PBM on 
VEGF concentrations indicates that the stimulation of VEGF secretion requires the 
activation of additional signaling pathways not induced by high glucose alone. 
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I. INTRODUCTION 
 
Diabetes 
 
Over 29 million people in the United States are currently diagnosed with diabetes 
mellitus (CDC 2014). Diabetes mellitus is a metabolic disease in which the body is 
unable to regulate glucose utilization, resulting in an asymptomatic increase in blood 
glucose concentrations referred to as hyperglycemia. Two pancreatic hormones, insulin 
and glucagon, are important in the regulation of blood glucose concentrations. 
Glucagon signals for the release of glucose into circulation, whereas insulin promotes 
the uptake of glucose. In diabetes, though, glucose utilization is impaired in one of two 
ways: by a lack of insulin production or by a defect in the body’s response to insulin. 
Under normal conditions, insulin is released by the pancreas in response to a rise in 
concentrations of glucose, free fatty acids, amino acids, and incretins. Within the 
pancreas, insulin is produced by pancreatic β-cells and secreted into the blood stream 
in response to elevated glucose concentrations. Once in the blood stream, insulin 
signals skeletal muscle and adipose tissue to take up glucose, restoring homeostasis. 
Glucose is then oxidized via the tricarboxylic acid cycle and mitochondrial electron 
transport chain to produce adenosine triphosphate (ATP), the primary cellular energy 
source. Inadequate insulin production or insulin signaling inhibits these processes, 
resulting in hyperglycemia. 
 
 
Although diabetes mellitus is incurable, alterations to lifestyle and drug therapies can 
assist in the maintenance of stable blood glucose concentrations. Treatment options are 
dependent on whether an individual is diagnosed with Type 1 or Type 2 diabetes. Type 
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1 diabetes results from an autoimmune induced destruction of the pancreatic β-cells, 
which eliminates insulin production. Therefore, treatment of type 1 diabetes requires 
insulin therapy throughout a patient’s life. Type 2 diabetes, however, is associated with 
insulin resistance and/or abnormal insulin secretion (Gullausseau et al. 2008). Unlike 
type 1 diabetes, type 2 diabetes can be managed, to some degree, by lifestyle changes, 
such as dietary modifications. Most type 2 diabetics, though, will also require insulin or 
oral hyperglycemic drug therapy to regulate blood glucose levels. 
 
 
Despite lifestyle changes and/or drug interventions to regulate blood glucose 
concentrations, long-term metabolic complications commonly develop in patients with 
either type 1 or type 2 diabetes. Diabetic complications occur with sustained tissue 
exposure to high circulating glucose and lead to micro- and macro-vascular 
complications throughout the body (Yamaoto et al. 2001, Aubert et al. 2014, Wu and 
Juurlink 2002, Wendt et al. 2003). Macrovascular damage increases the prevalence of 
heart disease, stroke, and peripheral arterial disease. Microvascular damage 
contributes to diabetic retinopathy (DR), neuropathy and nephropathy in diabetic 
patients. Cardiovascular disease, nephropathy, neuropathy, and DR are all considered 
major complications of diabetes. 
 
 
The most common diabetic complication, DR, is associated with vision loss as a result 
of vasculature development and rupture within the retina of the eye. A pathological 
increase in oxidative stress, promoted by mitochondrial dysfunction, increased signaling 
through the advanced glycation endproducts (AGE) and receptor of AGE (RAGE) 
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pathway, as well as increased activation of protein kinase C (PKC) are important for the 
development of DR (Kanwar et al. 2009, Wu and Juurlink 2002, Xia et al. 1994, Geralds 
et al. 2009). The symptomatic changes, which occur as a result of these pathways, take 
place in the retina. 
 
 
Anatomy of the Eye 
Anatomy of the Retina 
 
A healthy retina is essential for good vision. This light-sensitive tissue is located at the 
back of the eye and is the site of vision transduction. The neural retina is arranged in 
three cell layers. The rod and cone photoreceptor cells, which are responsible for visual 
transduction, are arranged in a layer against the back of the eyeball.  The second layer 
of cells, known as the inner nuclear layer, contains bipolar cells, horizontal cells, and 
amacrine cells. The surface layer of the retina is comprised of ganglion cells. The 
ganglion cell axons form the optic nerve which relays information to the brain. There are 
two synaptic regions in the retina: (1) the outer plexiform layer which contains the 
photoreceptor cell synapses which communicate with bipolar and horizontal cell 
dendrites and (2) the inner plexiform layer containing bipolar cell and amacrine cell 
synapses to ganglion cells.  Neurotransmitters, including glutamate, γ-aminobutyrate, 
 
glycine, acetylcholine, dopamine, and serotonin, are responsible for the signaling across 
the synapses. The Müller glial cells and retinal vasculature maintain retinal homeostasis 
by ensuring an adequate nutrient supply and eliminating waste. 
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Retinal Vasculature and Pericytes 
 
The blood supply to the retina is carried by the central retinal artery, the choroidal blood 
vessels, and their associated capillaries. These vessels provide oxygen while removing 
waste throughout the retina. Blood vessels throughout the body are lined with 
endothelial cells coated with pericyte cells, which forms the blood-retina barrier. The 
pericyte cells wrap around the endothelial cells of capillaries to provide stability, by 
maintaining the blood-retinal barrier, and by regulating blood flow (Jo et al. 2013, 
Peppiatt et al. 2006). 
 
 
 
The Müller Glial Cells 
 
The Müller glial cells are the principal glia in the retina. Müller glial cells support 
surrounding cells through the release of growth factors and antioxidants, and uptake of 
extracellular debris. Thus, functional changes in Müller glial cells can impact both 
neuronal and vascular cells in the retina. The anatomical localization of these cells 
throughout the retina allows for the maintenance of homeostasis, as well as providing 
structural and metabolic support to all cell types. The somata of Müller cells reside 
between either plexiform layer. Trunks extend from the somata in each direction, 
allowing Müller cells to span the width of the retina. Müller cells assist in the uptake and 
metabolism of retinal neurotransmitters. Regulation of neurotransmitters by Müller glial 
cells within the synapse prevents the inappropriate activation of neurons. Furthermore, 
the Müller cells support and maintain the blood-retinal barrier (Shen et al. 2012). 
Transgenic mice with conditional Müller glial cell dysfunction exhibited accelerated 
photoreceptor apoptosis, and blood-retinal barrier breakdown, resulting from weakened 
5  
tight junctions between endothelial cells (Shen et al. 2012). These observations 
substantiate the neural and vascular protective functions of the Müller cells. 
 
 
Examination of the Retina 
 
Imaging of the fundus (back of the eye) allows for visual inspection of the retina and 
macula, as well as the choroid and blood vessels. The majority of fundus examinations 
are conducted using a fundus camera, ophthalmoscope. These fundus images are 
principle for the determination of DR. In a healthy retina the macula, is devoid of blood 
vessels while in a diseased retina, the vasculature show signs of venular bulging and/or 
retinal thinning (Jonsson et al. 2016). 
 
 
 
Diabetic Retinopathy 
 
DR is the most common complication associated with diabetes, and it is the leading 
cause of blindness in the United States (CDC 2008).  The early stages of DR are 
typically asymptomatic, despite the underlying cellular and metabolic changes because 
there are no physically perceivable changes to vision (Wilkenson et al. 2003). These 
early stages are collectively referred to as the non-proliferative stage, which is 
characterized by microaneurysms, hemorrhages, exudates, and cotton-wool spots; 
which are indicative of nerve fiber damage. Notably, angiogenic changes do not develop 
during this early stage (Nayak et al. 2007). The development of retinal abnormalities is 
monitored by fundus imaging during yearly eye exams. The asymptomatic phase of DR 
is accompanied by retinal cell death, vascular swelling, and vascular leakage. 
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Diabetic patients with DR become aware of their disease when they progress to the 
proliferative diabetic retinopathy (PDR) stage, and visual changes are apparent. The 
progression of PDR is associated with pathological retinal angiogenesis.  The 
symptoms in this final stage initially begin with spotty vision and ultimately lead to 
blindness. These symptoms are caused by the inappropriate growth of weak blood 
vessels that can easily rupture. The spots in the field of vision occur with the leakage of 
blood from these weak vessels, as well as by excessive inflammation. The 
angiogenesis and inflammation in DR is associated with a number of different factors. 
Intracellular adhesion molecule-1 (ICAM-1) and vascular endothelial growth factor 
(VEGF) are two factors that have been implicated as playing a role in detrimental 
cellular changes within the retina. 
 
 
 
Cellular Changes in Diabetic Retinopathy 
 
Many cell types undergo functional alterations in the progression of DR.  These 
changes denote the progression and the severity of the disease. Pericyte cell loss, due 
to an increase in oxidative stress, is the first histopathological change in the 
development of DR (Amano et al. 2005). Pericyte loss promotes the hyperdilation of 
endothelial cells, and early vascular abnormalities. The degeneration of the retinal 
neuronal cells has also been purported to coincide with the inability of the vasculature to 
remove waste, and a change in function of the Müller glial cells (Frydkjaer-Olsen et al. 
2015). The Müller cells have, as well, been shown to shift from a primarily anti- 
inflammatory state to a pro-inflammatory state in the progression of DR (Gerhardinger 
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et al. 2005, Harada et al. 2006, Zong et al. 2010). Analysis of gene expression in Müller 
cells isolated from retinae of streptozotocin (STZ)-diabetic rats revealed an up- 
regulation of inflammatory-associated proteins (Gerhardinger et al. 2005). Thus, the 
biochemical and molecular changes that occur in Müller glial cells disrupt their function 
and result in vascular and neuronal cell dysfunction and death. 
 
 
 
Molecular Mechanisms of Diabetic Retinopathy 
Oxidative Stress 
 
At the molecular level, multiple pathways are involved in the pathological changes that 
occur during DR. However, many of these are not fully understood. Figure 1 illustrates 
pathways that have been associated with the overproduction of reactive oxygen species 
(ROS) leading to DR. These include mitochondrial dysfunction, the activation of PKC, 
and the production of AGEs (Kanwar et al. 2009, Wu and Juurlink 2002, Xia et al. 
1994). Additionally, there is decreased antioxidant function further promoting the 
development of oxidative stress (Kanwar et al. 2009). The increased level of oxidative 
stress further activates intracellular signaling pathways. In STZ diabetic rats, treatment 
with antioxidants, including, astaxanthin and curcumin, have been shown to alleviate the 
increased leukostasis, which may result from elevated levels of ICAM-1, and the 
induction of increased VEGF synthesis (Yeh et al. 2016, Obrosova et al. 2001). The 
combination of excessive ROS generation and antioxidant depletion are key factors in 
the development of DR. 
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Figure 1: Proposed Pathways Involved in the Development of DR 
The depiction of pathways involved in the progression of DR.  Early metabolic 
and antioxidant mitochondrial dysfunction induced by high glucose inhibits the 
metabolism of glucose as a result of reduced enzymatic activity of GAPDH. The 
build up of metabolites promotes the development of ROS through both the PKC 
and AGE-RAGE pathway. The development of oxidative stress has been shown 
to promote the inappropriate activation of NF-B leading to the excess synthesis 
of ICAM-1 and VEGF. 
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Mitochondrial Dysfunction 
 
Mitochondria are the primary source of ROS in the cell, and mitochondrial dysfunction is 
thought to be the initial source of oxidative changes that occur in DR (Trudeau et al. 
2006). Trudeau et al. observed early structural and functional changes of mitochondria 
in rat retinal endothelial cells grown in high glucose medium (30 mM), in comparison to 
those cultured in low glucose medium (Trudeau et al. 2006). After 30 minutes of 
exposure to high glucose conditions, the mitochondria of the rat retinal endothelial cells 
exhibited fragmented membranes. Mitochondrial membranes structure recovered to 
normal within two hours of high glucose treatment (Trudeau et al. 2006). However, 
when rat retinal endothelial cells were cultured in high glucose for a minimum of 48 
hours, mitochondrial fragmentation continued for the remainder of the 6-day analysis. 
Additionally, when rat retinal endothelial cells were cultured in high glucose for three or 
six days, there was a significant reduction in oxygen consumption and an increase in 
the release of cytochrome c indicating a change in mitochondrial metabolism (Trudeau 
et al. 2006). These changes in mitochondrial function caused deregulation of many 
cellular systems due to a reduction in ATP synthesis and increased production of ROS. 
 
 
In addition to impaired mitochondrial function, the increase production of ROS by the 
mitochondria impairs glucose metabolism, resulting from a reduction in the enzymatic 
function of glyceraldehyde-3-phosphate (GAPDH). The impaired enzymatic function of 
GAPDH has been linked to dysfunction in antioxidant mechanisms (Kanwar et al. 2009). 
In retinal endothelial cells maintained under hyperglycemic conditions, mitochondrial 
superoxide dismutase, an enzyme known to scavenge ROS, is diminished (Kowluru et 
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al. 2006). Furthermore, under hyperglycemic conditions, overexpression of 
mitochondrial superoxide dismutase restored GAPDH function (Xueliang et al. 2003). 
The inhibition of GADPH, as observed in diabetes, leads to the build-up of glucose 
metabolites, including glyceraldehyde 3-phosphate. The accumulation of high 
concentrations of these glucose metabolites promotes further downstream activation of 
pathways including the PKC and AGE-RAGE pathway (Figure 1). Increased activation 
of these signaling cascades further promotes an increase in oxidative stress. 
 
 
ROS Activation of Intracellular Signaling 
 
Collectively, the development of oxidative stress results in the activation of pathways 
involved in inflammation and angiogenesis primarily through activation of nuclear factor- 
B (NF-B) (Soufi et al. 2012). Indeed, the activation of NF-B is considered an 
important step in the progression of DR (Nagai et al. 2007, Zhao et al. 2012, Romeo et 
al. 2002, Zheng et al. 2004), specifically due to its regulation of ICAM-1 and VEGF 
(Mamputu et al. 2004, Shelton et al. 2007 Cervellati et al. 2014).  ICAM-1 is an 
important adhesion molecule involved in the inflammatory response associated with DR 
(Mamputu et al. 2004, Joussen et al. 2001).  During normal function, ICAM-1 functions 
to facilitate leukocyte transmigration by allowing attachment and migration of leukocytes 
through blood vessels. However, when produced in excess, ICAM-1 leads to an 
inordinate degree of leukostasis, which was observed in a STZ-induced diabetic rat 
model of DR (Tang et al. 2013). This increase in leukocyte adhesion correlated with 
increased endothelial cell apoptosis (Joussen et al. 2001). The accelerated loss of 
endothelial cells alters the structure of the vasculature, resulting in leakage and the 
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rupture of blood vessels and, thus, impairing the adequate blood flow within the 
vasculature (Joussen et al. 2001). 
 
 
With the impaired vascular function, the reduced blood flow to the retina promotes an 
ischemic environment. To enable restoration of appropriate tissue oxygen 
concentrations, angiogenesis is stimulated. Normally, angiogenesis is important for 
improved blood flow in areas where the vasculature is damaged. However, in DR, 
overproduction of VEGF leads to excess growth of these blood vessels, which impedes 
vision. Vision loss occurs as a result of vessel growth and leakage of blood near the 
macula. Also, irreversible vision loss takes place after extensive blood vessel growth 
promotes the formation of a fibrovascular membrane (FVM). The surgical removal of 
FVMs is frequently required to prevent retinal detachment and permanent loss of vision 
(Kim et al. 2015). 
 
 
 
Treatment of Diabetic Retinopathy 
 
Therapeutic options for diabetic patients with DR depends on how pronounced their 
retinal abnormalities are. During the early stages of DR, the treatment includes 
continued control of diet and blood pressure (Liu et al. 2013). As DR progresses, 
therapies are directed at inhibiting the inappropriate growth of blood vessel. These 
treatments are monoclonal antibodies designed to neutralize VEGF and thus are 
referred to as anti-VEGF therapy (Yang et al. 2013). Individuals with PDR that abstain 
from treatment will progress to severe vision loss and eventually become blind. 
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Currently, anti-VEGF therapies are the gold standard of treatment for DR. Although, 
photocoagulation therapy is often used in conjunction with the anti-VEGF therapies. 
This treatment regimen employs a high-intensity laser to seal or destroy damaged and 
leaking vessels in the retina (Yang et al. 2013). If these steps are performed before 
retinal damage, the reversal of vision loss is likely (Yang et al. 2013). 
 
 
Current treatment strategies for patients with DR reduce vision loss. However, 
significant side effects are associated with their use. Some common side effects of 
therapies for DR include scotoma (blind spot), retinal scarring, macular edema, and/or 
vitreous hemorrhage (Sher et al. 2013, Shin et al. 2009). In addition to these side 
effects, the therapeutic effects of these treatments diminish in a short period of time. 
One study showed improvement of visual acuity in 17 patients treated with intravitreal 
bevacizumab, an antibody against VEGF. However, visual acuity declined to baseline 
by three months following treatment, indicating a need for repeated treatments (Preti et 
al. 2012). Targeting the VEGF signaling cascade is just one of many plausible 
therapeutic options for control of DR. Another possible therapeutic would include 
targeting upstream molecules which may have equal or greater beneficial effects. One 
such target that has gained interest is modification of the transcriptional activity of NF- 
B, a transcription factor that has been shown to play a role in the progression of DR 
(Nagei et al. 2007, Soufi et al. 2012). 
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NF-κB’s Role in Diabetic Retinopathy 
 
NF-B activation is an important factor in the progression of DR, because of its 
regulatory effects on proteins involved in inflammation and retinal angiogenesis (Figure 
1). NF-B also plays a beneficial role in many other cellular processes, including 
inflammation, immunity, cell proliferation, differentiation, and survival. This diverse 
functionality of NF-B is a result of extensive various subunits and methods of 
activation. The need for diverse NF-B function is due to variability amongst cell types, 
differences in phosphorylation, and other post-translational modifications (Romeo et al. 
2002, Werner et al. 2005, Brown et al. 1994). 
 
 
Generally, NF-B is maintained in the cytoplasm when dimerized by IB. Once NF-B 
is activated, at least 150 genes have been reported to be under the transcriptional 
regulation of NF-B (Ghose and Bhattacharyya 2015). Three pathways are involved in 
the activation of NF-B, including the canonical, non-canonical, and ROS-activated. In 
DR, the overproduction of ROS promotes the inappropriate and over activation of NF- 
B. Regulation of NF-B activity may provide a therapeutic target for DR. Previous 
studies show that inhibition or reduced activation of NF-κB slows the progression of DR. 
Nagei et al. (2007) inhibited NF-κB in a STZ diabetic mouse model of DR with 
dehydroxymethylepoxyquinomicin, reducing inflammation and slowing progression of 
DR compared to vehicle treatment only groups (Nagai et al. 2007). However, due to the 
vast role of NF-B in regulating cellular function, long-term inhibition may not be 
beneficial. 
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In a similar study, Soufi et al. treated STZ diabetic mice with resveratrol, a plant-based 
antioxidant compound (Soufi et al. 2012). Resveratrol treatment resulted in decreased 
NF-κB activation, as measured by antibody binding of the p65 subunit in nuclear 
extracts (Soufi et al. 2012). Furthermore, the treatment reduced apoptosis and 
inflammation (Soufi et al. 2012). These changes likely occur as a result of attenuating 
oxidative stress. Thus, attenuation of NF-B activation by ameliorating hyperglycemia 
induction of oxidative stress may present an alternative therapeutic target for the 
treatment of DR. 
 
 
 
Photobiomodulation 
Photobiomodulation 
 
A potential alternative therapy for DR includes treatment with far-red to near-infrared 
(NIR) light (630 nm-1000 nm).  This light treatment has been shown to cause a 
biological change including mitigation of oxidative stress, repair of mitochondrial 
function, and prevent cell death, and is, thus, commonly referred to as 
photobiomodulation (PBM) (Ball et al. 2011). Treatment with low-energy lasers or light- 
emitting diode (LED) arrays has been reported to be beneficial in models of tissue repair 
and wound healing (Gaida et al. 2004, Gupta et al. 2015, Pinto et al. 2009).  In a model 
of wound healing, Sprague-Dawley rats treated with 904 nm light had a higher healing 
efficacy on the induced burn wounds compared to treatment with sulfadiazine cream, a 
common burn therapy (Gupta et al. 2015). Furthermore, PBM has shown promise in 
clinical trials for the treatment of mucositis and stroke. 670 nm light reduced the 
incidence of mucositis in the treatment patients undergoing a bone marrow transplant 
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(Hodgson et al. 2012, Whelan et al. 2002). In clinical trials of PBM in stroke patients, 
light therapy has shown promise in both safety and improved outcomes (Zivin et al. 
2009, Lampl et al. 2007). Taken together, studies involving PBM have shown beneficial 
effects in the disease models chosen.  Understanding treatment with far-red to NIR 
light, though, remains challenging due to varying effects observed between wavelengths 
and dosage.  For example, rats with burn wounds received treatment with 670 nm light 
at a range of dosages (1, 5, 9, and 19 J/cm2) or received sham treatment for either 
three or five days a week. Animals which received treatment with 670 nm light at a 
dosage of 1 J/cm2 had a significantly higher rate of healing than rats treated with the 
various other dosages, as well as rats which received sham treatment (Al-Watban and 
Delgado 2005). Additionally, the wavelength selected for treatment has differential 
effects. Comparative analysis of treatment with 665, 730, 810, and 980 nm light (36 
J/cm2) was performed in a mouse model of traumatic brain injury (TBI) (Wu et al. 2012). 
TBI was induced in adult male BALB/c mice by the controlled drop of a weight onto their 
skull. Animals received a single dose of their respective treatment fours-hours post-TBI 
(Wu et al. 2012). Mice performed various tasks for measurement of neurological injury 
from post-injury day 0 to postinjury day 30 (Wu et al. 2012). Animals treated with 665 
and 810 nm light post-injury had a significant improvement in neurological function in 
comparison to TBI control animals (Wu et al. 2012). However, there was no significant 
difference in neurological function between animals treated with 730 nm or 980 nm light, 
compared to animals which were sham treated (Wu et al. 2012). Therefore, 
understanding treatment with light in the far-red to NIR range remains challenging due 
to varying effects observed between wavelengths and dosage. The beneficial effects of 
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treatment with light in the far-red to NIR range reported thus far, support further 
investigation into optimal dosages and wavelengths. 
 
 
Photobiomodulation in Models of Oxidative Stress 
 
Beyond the alleviation of symptoms, another therapeutic effect observed after treatment 
with PBM is the diminution of oxidative stress. In a number of models, of which oxidative 
stress has pathological significance, treatment with far-red to NIR light has been shown 
to reduce oxidative stress and alleviate symptoms and or pathological markers of the 
disorder (Tang et al. 2013, Saliba et al. 2015, Silva Macedo et al. 2015, Purushothuham 
et al. 2014). In cell culture models of oxidative stress, PBM was able to diminish ROS. 
ARPE-19 cells, immortalized retinal pigment epithelial cells, and human primary retinal 
pigment epithelial cells treated with hydrogen peroxide showed diminished ROS when 
treated with 670 nm light.  The authors report that although ROS is diminished, it was 
not to a sufficient level to preserve mitochondrial membrane potential and reduce cell 
death (Fuma et al. 2015). Similarly, a reduction in both NO and ROS was observed in 
dental pulp cells treated with LPS and 855 nm light (Montoro et al. 2014). 
 
 
Similar results were observed in vivo. Male 2-month-old Wistar rats were exposed to 
formaldehyde (1%, 90 in), as a model of acute lung inflammation, and treatment with 
660 nm light decreased oxidative stress while simultaneously increasing the presence 
of antioxidants in comparison to non-treated rodents exposed to formaldehyde (Silva 
Macedo et al. 2016). Furthermore, in two different mouse models of Alzheimer’s 
disease five month K3 mice and seven month APP/PSI mice were treated for 90 
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seconds with 670 nm light for five days per week over a four-week period, which 
resulted in reduced lesion size in comparison to non-treated Alzheimer’s mice 
(Purushothuham et al. 2014). Corresponding to these reductions in pathological 
markers was a decrease in the presence of 8-hydroxy-2’-deoxyguanosine, a marker of 
deoxyribonucleic acid (DNA) oxidative damage (Purushothuham et al. 2014). These 
studies are just a few examples demonstrating the effects of PBM on oxidative stress 
and disease manifestations. 
 
 
Photobiomodulation in Retinal Disorders 
 
Several studies using 670 nm light on retinopathies have demonstrated therapeutic 
effects for this treatment. For example, in Long Evans rats treatment with 670 nm LED 
has been used to protect against the toxic effects of methanol (Eells et al. 2003). 
Methanol exposure leads to formic acid production and metabolic acidosis resulting in 
injury to the retina and optics nerve as observed through abnormal ERGs. Additionally, 
methanol treatment leads to histological abnormalities including retinal swelling and 
disruption of the mitochondria in photoreceptors (Eells et al. 2003). These symptomatic 
and histological changes observed in methanol-intoxicated rodents were significantly 
reduced in animals treated with 670 nm light for 144 seconds at a dosage of 4.5 J/cm2, 
at 5, 24, and 50 hours after intoxication (Eells et al. 2003). In a rodent model of retinitis 
pigmentosa, treatment with 670 nm light also regulates cytoprotection and reduces the 
loss of photoreceptors (Machida et al. 2013). Furthermore, retinal function was 
improved in animals treated with 670 nm light compared to control (Kirk et al. 2013). 
Treatment with 670 nm light also promotes improvements in visual acuity in age-related 
18  
macular degeneration (AMD) (Merry et al. 2013). In a small patient sample, nine 
individuals with AMD received treatment with 670 nm light at 50-80 W/cm2, 4-7.68 
J/cm2, and a duration of 88 +/- 8 seconds three times per week for six weeks. Patients 
treated with 670 nm light had a significant improvement in visual acuity, when compared 
to measures of visual acuity collected prior to treatment (Merry et al. 2013). 
 
 
 
Photobiomodulation in Models of Diabetic Retinopathy 
 
Collectively, previous studies show that PBM attenuates oxidative stress and 
ameliorates disease manifestations in retinal disorders. It is, therefore, likely that PBM 
may be beneficial for the treatment of DR. 670 nm light treatment of retinal ganglion 
cells, Muller glial cells and RPE cells cultured in high glucose concentrations to simulate 
diabetes reduced superoxide production and cell injury (Tang et al. 2013).  In the STZ 
rat model of DR, 670 nm light treatment at the onset of diabetes, significantly reduced 
the development of lesions, leukostasis, and reduced the increase in ICAM -1 synthesis 
associated with disease (Tang et al. 2013). Similar observations were made in the STZ- 
mouse model of DR (Saliba et al. 2015). Additionally, Saliba et al. reported that 670 nm 
light treatment of advanced stage diabetes in rodents also slowed disease progression 
(Saliba et al. 2015). A recent series of case reports also provides clinical evidence that 
670 nm light reduces retinal edema associated with diabetes (Tang et al. 2015). Beyond 
these findings, little is known about the intracellular effects of PBM in models of DR; 
however, work in other areas has helped provide insight behind the mechanism of 
action for PBM. 
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Mechanism of Action of PBM 
 
Therapeutically beneficial effects of PBM have been observed in a number of disorders 
such as Alzheimer’s disease, wound healing, and various retinal diseases 
(Purushothuham et al. 2014, Gupta et al. 2015, Eells et al. 2003, Tang et al. 2013). The 
improved functional outcomes and diminution of disease causing lesions have been 
found to coincide with an improvement in mitochondrial function (Cummins et al. 2013). 
Mitochondrial dysfunction is an early step in the development of an assortment of 
disorders, particularly in the retina, a mitochondrial rich environment (Trudeau et al. 
2006, Marshall et al. 2015, Maleki et al. 2013). Photobiomodulation has been shown in 
several studies to modulate mitochondrial function (Agrawal et al. 2014, Cummins et al. 
2013, Wong-Riley et al. 2005). In a rodent model of optic nerve injury, mice were either 
sham treated or treated with 670 nm LED (88 seconds, 60 mW/cm2, 5 J/cm2), for one or 
seven days after injury. Sham-treated mice with optic nerve injury presented with a 
change in mitochondrial structure and activity, as determined by transmission electron 
microscopy. The changes to the mitochondrial structure in the model of optic nerve 
injury were attenuated in the injured mice receiving 670 nm light (Cummins et al. 2013). 
The effects of NIR light on mitochondrial function has been hypothesized to induce 
functional changes in the mitochondrial photoacceptor molecule, cytochrome c oxidase 
(CcO). In cultured primary neurons, treatment with 670 nm light significantly increased 
the activation of CcO leading to improved mitochondrial function as indicated by an 
increase in ATP synthesis (Wong-Riley et al. 2005, Agrawal et al. 2014). Furthermore, 
treatment of primary neurons with 670 nm light protected from induced cell death by 
potassium cyanide, an inhibitor of CcO (Wong-Riley et al. 2005). Recent studies have 
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shown that NIR irradiation results in redox alterations in the CcO complex activating 
intracellular signaling cascades which culminates in improved mitochondrial function 
and increased synthesis of cytoprotective factors (Ball et al. 2011, Demontis et al. 
2002). Beyond these findings, due to the prolonged effect of brief treatment with light in 
the far-red to NIR range, it is likely that PBM induces a cascade of events leading to the 
stimulation of gene expression, protein synthesis, and oxidative metabolism. Although 
the mechanism has not been fully elucidated, it has been postulated that the light 
photons modify the structure of CcO, improving electron transport and increasing ATP 
production (Lohr et al. 2009). Also, it has been observed that light treatment culminates 
in the release of a small burst of ROS or nitric oxide (NO) and activation of transcription 
factors which modulate gene transcription (Lohr et al. 2009, Zhang et al. 2009). 
Naturally, CcO can bind either oxygen or NO on the heme of iron or copper center. As 
suggested by Lohr et al. a NIR photon photodissociates NO from CcO of mitochondria 
with abnormal function. The release of NO promotes oxygen to bind CcO and re- 
establish mitochondrial function. This release of NO is referred to as the burst, and may 
promote transcription (Figure 2). In regards to mitochondrial associated genes, gene 
transcriptional changes after light treatment result in the upregulation of cytoprotective 
cytokines, as previously mentioned, and antioxidants such as mitochondrial superoxide 
dismutase (Agrawal et al. 2014, Huang et al. 2013, Zhang et al. 2003, Tang et al. 2013). 
 
 
Additionally, treatment with light in the NIR spectrum has been found to increase the 
expression of CcO in an animal model of AMD (Begum et al. 2013). In the complement 
factor H knockout (CHF -/-) mouse model of AMD, animals were exposed to 670 nm 
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LED for 6 minutes twice a day (Begum et al. 2013). This NIR treatment was continued 
for 14 days. The CHF -/- mice exposed to light treatment had a significant increase in 
CcO as measured by immunostaining in sectioned eyes in comparison to those 
collected from sham-treated CHF-/- animals (Begum et al. 2013). Collectively, these 
studies further provide evidence that treatment with PBM promotes improvement to 
mitochondrial activity through changes in mitochondrial-associated gene regulation 
(Begum et al. 2013). 
 
 
Microarray analysis was used to elucidate additional pathways and cellular changes that 
occur after treatment with PBM. Gene expression profiles performed on treated human 
fibroblasts indicate that PBM regulates 111 genes.  The genes regulated by PBM 
include those involved in cell proliferation, suppression of apoptosis, cell growth, redox 
regulation, and mitochondrial energy metabolism (Song et al. 2003). While CcO is a 
likely photoacceptor molecule, other downstream transcriptional changes occur which 
may or may not result from CcO activation. Therefore, additional research is needed to 
determine PBM mechanism. 
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Figure 2: Image Depicting the Theorized Effects of PBM on CcO 
Work by Lohr et al. (2009) and Zhang et al. (2009) suggests that in a state of 
mitochondrial dysfunction CcO preferentially binds NO over oxygen. Treatment 
with NIR light photodissociates NO, therefore allowing oxygen to bind. This 
binding of oxygen promotes improvement to mitochondrial function and sub 
sequentially induces changes in activation of transcription factors and gene 
transcription. ( represents a change) 
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Effects of Photobiomodulation on NF-B 
 
In a small assortment of models, PBM has been found to modulate the activation of the 
transcription factor NF-B. In a rodent model of burn healing, animals treated with 904 
nm (0.2 J/cm2) light for either 4 or 7 days post injury exhibited a decrease in NF-B 
translocation to the nucleus (Gupta et al. 2015). Although this is not a direct measure of 
transcriptional activity, it is indicative of a reduction in the activation of NF-B. 
Interestingly, differential observations were reported by Mafra de Lima et al. (2009) in 
regards to the effects of far-red to NIR light treatment on the activity of NF-B. Bronchi 
from Wistar rats were dissected and treated with 655 nm at a dose of 2.6 J/cm2 (Mafra 
de Lima et al. 2009). After treatment, relaxation of bronchi smooth muscles was 
restored.  When an NF-B antagonist was introduced, these effects were blocked. 
Therefore, in this model, NF-B activation by 655 nm is preferential (Mafra de Lima et 
al. 2009). Outside of these studies, little is known about the effects PBM has on NF-B 
activity in additional models or with regard to other treatment protocols. The varying 
effects of PBM on NF-B activity could be due to the dual role of NF-B, for eliciting 
either a pro-inflammatory or anti-inflammatory response, or differences between cell 
type studies and the manner in which NF-B was activated (Liu et al. 2007, Fong et al. 
2008). These conflicting results highlight a need for additional research to understand 
the effect of PBM on NF-B transcriptional activity. Analyzing the effects of PBM on NF- 
B in a model of DR may help clarify inconsistencies. 
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Summary and Gap in Knowledge 
 
The progression of DR has been linked to increased activity of NF-B, as well as 
increased levels of ICAM-1 and VEGF (Mamputu et al. 2004, Lennikov et al. 2004). It is 
well established that NF-B activation occurs in response to elevated ROS (Kowluru et 
al. 2003, Kowluru et al. 2007, Wautier et al. 1994). Furthermore, 670 nm light has been 
shown to inhibit oxidative stress associated with pathological changes in the 
development of DR. Tang et al. confirmed that the inhibition of oxidative stress was 
correlated with a decrease in ICAM-1 levels and leukostasis (Tang et al. 2013). Beyond 
this work, little is known about changes in intracellular signaling and transcriptional 
activity. Research by Gupta et al. and Mafra et al. investigated the effects of PBM on 
NF-B activity, however, the observed changes in NF-B activity were dependent on 
the models analyzed (Gupta et al. 2015, Mafra de Lima et al. 2009). PBM modulation of 
signaling in the retina has yet to be elucidated. We have conducted studies to 
characterize the mechanisms by which 670 nm light affects retinal signaling pathways in 
a cultured cell model of DR. These studies examine the effects of 670 nm light on 
activation of NF-B and cellular level of ICAM-1 and VEGF in a Muller glial cell model of 
DR. 
 
 
To perform these studies, Müller glial cells were cultured in either normal or high 
glucose to replicate normoglycemic and hyperglycemic conditions. Groups from each 
culture condition received either 670 nm LED treatment at a dosage of 4.5 J/cm2 or 
sham treatment. These conditions allowed for analysis of hyperglycemic conditions in 
the selected model, as well as determine the therapeutic effects of 670 nm LED 
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treatment on attenuation of hyperglycemic-induced differences. The Müller glial cell 
model was selected because of their principle role of maintaining homeostasis for both 
the vasculature and for neuronal cells. Thus, the ability to modulate hyperglycemic- 
induced changes in Müller glial cells may be biologically important for ameliorating 
changes in additional cell types. 
 
 
 
II. HYPOTHESIS AND SPECIFIC AIMS 
 
DR is the leading cause of blindness in the United States and accounts for 10,000 new 
cases annually. The early stages of disease are asymptomatic despite the induction of 
mitochondrial dysfunction, increased AGE-RAGE interaction, and excess activation of 
PKC pathways, resulting in an increase in oxidative stress. This, in turn, leads to 
increased inflammation and retinal neovascularization, due in part to the activation of 
NF-κB (Mamputu et al. 2004, Shelton et al. 2007).  Two of the proteins regulated by NF- 
B and involved in inflammation and retinal neovascularization, ICAM-1 and VEGF, are 
implicated in the progression of DR and loss of vision. 
 
 
Intraocular injections of anti-VEGF agents is the current therapy for DR; however, this 
approach is invasive and subject to undesirable side effects (Yang et al. 2003). PBM 
using 670 nm LED arrays is currently under investigation as a potential therapeutic 
option. Tang and colleagues have shown that 670 nm light attenuates DR in an 
experimental rat model of DR and in patients with diabetic non-center edema (Tang et 
al. 2013, Tang et al. 2015, Saliba et al. 2015). In the STZ-diabetic rodent model of DR, 
an observable reduction in leukostasis, which correlated with the reduction in ICAM-1 
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was also observed when animals were treated with 670 nm LED (Tang et al. 2013). 
Additionally, these observations corresponded to a reduction in oxidative stress. Based 
on the relationship between the induction of oxidative stress and the increase activation 
of NF-κB, as well as the relationship between increased activity of NF-κB and levels of 
ICAM-1 and VEGF in DR, we predict that PBM will reduce NF-κB activity and reduce 
the relative level of ICAM-1 and concentration of VEGF. Therefore, we hypothesize that 
in an in vitro model of DR, PBM will reduce the activity of NF-κB, and reduce the level of 
ICAM-1 and concentration of VEGF. Characterization of the effects of PBM on NF-κB 
activity and changes in the level of ICAM-1 or VEGF will advance our understanding of 
the mechanism of action of PBM. Mechanistic studies are essential to move this 
treatment modality into the clinic for treatment of DR. We plan to test this hypothesis 
with the following specific aims: 
 
 
Specific Aim 1: Determine the effects of PBM on the activity of NF-κB. 
Working Hypothesis: PBM will reduce activation of NF-κB in a model of DR. 
 
 
Specific Aim 2: Determine the effects of PBM on the levels of VEGF and ICAM-1. 
 
Working Hypothesis: PBM will reduce the concentration of VEGF and the level of 
ICAM-1 in a model of DR. 
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III. MATERIALS AND METHODS 
 
Cell Line 
 
Müller glial cells are in direct contact with multiple cell types in the retina and are 
important for the maintenance of homeostasis. Prior research analyzed changes in 
Müller glial cells cultured under hyperglycemic conditions. High glucose culture 
conditions resulted in an increase in transcriptional activity of NF-B (Shelton et al. 
2009). It has also been observed that under hyperglycemic conditions Müller glial cell 
production ICAM-1 and VEGF and ICAM-1 is increased (Bai et al. 2009, Shelton et al. 
2007). Thus, Müller glial cells develop abnormalities consistent with those observed in 
DR, and this model will facilitate the analysis of the actions of PBM on intracellular 
signaling systems. Because we are using a cell culture model, we can examine 
signaling within one cell type. However, because we are using an isolated cell culture 
system, signaling which naturally occurs between cell types cannot be examined and 
will require further work in an animal model. For the scope of this study, an isolated cell 
culture system is ideal to better understand intracellular signaling activated by 670 nm 
light. 
 
 
 
Culture Conditions 
 
Immortalized rat Müller glial cells (rMC) were obtained from John Mieyal at Case 
Western Reserve University. Stock cells were maintained in a solution of 10% DMSO in 
10% FBS with Dulbecco’s Modified Eagle’s Medium (DMEM) and stored in liquid 
nitrogen. For tissue culture experiments, cells were suspended in DMEM with 1% 
penicillin-streptomycin, 10% heat-inactivated fetal bovine serum (HI-FBS), and 110 
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mg/L sodium pyruvate. For light treatment experiments, cells were cultured for up to six 
days in either high (25mM) or normal (5 mM) glucose with 1% penicillin-streptomycin, 
2% HI-FBS and 110 mg/mL sodium pyruvate. Media was replaced daily, or twice daily 
for transfected cells to maintain stable glucose concentrations. As shown in Table 1 
samples collected on the last day of treatment indicate that levels of glucose were 
maintained for cells cultured in 100 mm dishes. However, for cells cultured in a six-well 
dish culture glucose levels were not maintained for the full 24 hours. Therefore media 
was changed every 12 hours to retain stable glucose concentrations (Table 2). Cultures 
were stored in a 37°C incubator with 5% CO2. For six well or 100 mm plates, 20,000 
cells/well or 80,000 cells/100 mm dish were plated, respectively. 
 
 
Table 1: Glucose Levels After 24 Hours of Incubation 
 
Sample Calculated Glucose Concentration 
Normal Glucose (stock media) 1.86 mg/mL 
High Glucose (stock medial) 5.78 mg/mL 
Normal Glucose (100mm dish) 1.53 mg/mL 
High Glucose (100 mm dish) 6.12 mg/mL 
Normal Glucose (6 well plate) 0.54 mg/mL 
High Glucose (6 well plate) 5.93 mg/mL 
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Table 2: Low Glucose Levels After 12 Hours of Incubation 
 
Sample Calculated Glucose Concentration 
Normal Glucose (Control) 1.75 mg/mL 
Normal Glucose (6 well dish) 1.43 mg/mL 
 
 
 
 
670 nm light Treatment 
 
Cultures were treated once daily between 11:00 – 12:00 pm. Cells cultured in high or 
low glucose were placed on the surface of the 670 nm 75 cm2 LED array (Spectralife, 
QDI, Barneveld, WI) (Table 3). PBM treatment consisted of 670 nm irradiation for 180 
seconds at a power intensity of 25mW/cm2, resulting in an energy density of 4.5 
Joules/cm2 (0.025 W/cm2 x 180 sec = 4.5 J/cm2). Sham-treated cells were handled in a 
similar manner, except the LED device was not turned on. Cells were either light- or 
sham-treated for three days (NF-B assessment) or 5 days (ICAM-1 and VEGF 
assessment) depending on assay protocol. Following treatment, conditioned media 
and/or cell lysates were collected and stored at -80°C for future processing. 
 
 
Table 3: Summary of Treatment Regimen for Experimental Groups 
 
Group Media Treatment 
1 
High Glucose 
(FBS+25mM Glucose) 
Light 
2 
High Glucose 
(FBS+25mM Glucose) 
Sham 
3 
Normal Glucose 
(FBS+5mM Glucose) 
Light 
4 
Normal Glucose 
(FBS+5mM Glucose) 
Sham 
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Plasmid Growth and Purification 
 
DH5 α bacterial cells, containing NF-B or Renilla plasmids, were obtained from John 
Mieyal at Case Western Reserve University. To initiate a starter culture, stabs from 
frozen stock cultures (maintained in 20% glycerol) were incubated in lysogeny broth 
(LB) containing 100 μg/mL ampicillin.  A starter culture (5mL) was incubated overnight 
at 37°C shaking at 300 rpm. After initial incubation, the starter culture was added to 250 
mL of LB broth containing 100 μg/mL ampicillin and allowed to shake at 300 rpm 
overnight at 37°C. The following DNA purification steps were performed utilizing a 
Maxi-prep kit from Qiagen and performed per manufacturer instructions. Transfection of 
the plasmids was confirmed by gene sequencing, which was performed by Angela 
Schmoldt at the School of Freshwater Science, University of Wisconsin-Milwaukee. 
Forward and reverse primers were designed for sequencing of both the NF-B and 
Renilla plasmid. Table 4 shows the designed primer sequences for amplification of the 
transfected plasmids. BLAST was used for the comparison and confirmation of 
transfection. 
 
 
Table 4: Primers Used for Gene Sequencing 
 
Plasmid Primer Sequence 
NF-B forward primer 5'CACCTCCCCC TGAACCTGAA AC3' 
NF-B reverse primer 5’CCTCTAGAGGATAGAATGGC3’ 
Renilla forward primer 5’CGAATTCGAACACGCAGATG3’ 
Renilla reverse primer 5’CTGCATTCAGTTGTGGTTTG3’ 
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Transfection of Müller glial cells with Luciferase and Renilla Plasmids 
 
To transfect Müller glial cells, 20,000 cells/well were plated in a six-well dish. After 
three days in culture, cells were approximately at a confluence of 60-70%. Cells were 
washed twice with 1x phosphate buffered saline (PBS). They were then co-transfected 
with a NF-B and Renilla plasmid. Transfection was performed with a cocktail 
containing 1 mL/well Opti-MEM, 5 μL/well lipofectamine, 1 μg/well NF-B plasmid and 
0.1 μg/well Renilla plasmid (Shelton et al. 2007). Transfection was allowed to proceed 
for 8 hours. Following transfection, the transfection cocktail was aspirated and replaced 
with DMEM, 5 mM glucose, 2% FBS, 1 % penicillin-streptomycin, 110 mg/L sodium 
pyruvate for 3-4 hours. Media was again aspirated and replaced with appropriate 
culture media, high (25 mM) or normal (5 mM) glucose. Cells were maintained in either 
high or normal glucose conditions for three days and were either treated with 670 nm 
light or sham treated for 180 seconds daily. At the completion of the treatment, lysates 
were collected in 1x passive lysis buffer and stored at -80°C until further analysis. 
 
 
 
Measurement of NF-B Transcriptional Activity 
 
A Biotek Synergy HT plate reader was used for detection of luminescence. Luciferase 
readouts were normalized to Renilla readings. The Renilla sequence provides an 
internal control because it is constitutively expressed, and not affected by the treatment. 
If transfection does not occur equally between groups, the Renilla luminescence 
provides a method for the normalization of data. 
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Cell Collection and Lysate Processing for ICAM-1 analysis 
 
For cell collection, plates were first washed with 1X PBS and cells were then detached 
with trypsin.  Trypsinization was stopped by adding 8 mL of growth media to the 100 
mm plate. Next, cells were centrifuged at 1,000 x g for 5 minutes. The pellet was 
washed with 1 mL of 1X PBS and centrifuged at 1,000 x g for 5 minutes. Lysis was 
performed on ice for 20 minutes in 100 µl of 1X RIPA buffer and 1X protease inhibitor 
cocktail (Thermo Scientific) at a dilution of 1:100. The lysate was then centrifuged at 
15,000 x g for 5 minutes to pellet cellular debris. A Pierce™ Bicinchoninic Acid Assay 
Kit from Thermo Scientific (catalog number 23225) was used, according to 
manufacturer protocol, to determine protein concentration in the supernatant. Each 
sample was analyzed at a dilution of 1:5, 1:10, and 1:20 with PBS and absorbance was 
measured at 570 nm. The standard curve for determining protein concentration ranged 
from 0 mg/mL to 1 mg/mL. 
 
 
 
Assessment of ICAM-1 Levels in Müller glial Cell Culture 
 
A Western blot was used to compare the relative amount of ICAM-1 between treatment 
groups. 100 µg of cell lysate was analyzed for each sample. Each sample was 
incubated at 95° C for 15 min with 1x sample buffer (10% glycerol, 2% SDS, 0.01% 
bromophenol blue, 200 mM Tris-HCl pH 6.8, 20 mM dithiothreitol) to denature proteins. 
PBS was added to each sample so that each had a volume of 25 µL. Samples were 
separated on a 12% polyacrylamide Mini-PROTEAN ® TGX Precast Gel (Biorad) along 
with a protein ladder (Biorad).  The gel electrophoresis was performed in running buffer 
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(0.3% w/v Tris Base, 1.45% w/v Glycine, 0.1% w/v SDS) at 200 volts for 1 hour to 
separate proteins. 
 
 
Proteins resolved by electrophoresis were transferred to a polyvinyl difluoride (PVDF) 
membrane. Prior to transfer, the membrane was soaked in methanol for 2 minutes and 
then washed with Transfer Buffer (0.3%w/v Tris, 1.45% w/v glycine, and 10% v/v 
methanol). The gel was sandwiched between 2 sponges and filter papers soaked in 
transfer buffer and placed into a cassette.  Transfer of the proteins proceeded for 16 h 
at 100 mA and 4°C. Following transfer, the PVDF membrane was blocked with 1% 
bovine serum albumin (BSA) in 1X Tris-buffered saline (TBS; 0.3% w/v Tris-HCl, 0.88% 
w/v NaCl) + 0.1% Tween 20 (TBST) for one hour. The membrane was then washed 
three times for 10 minutes each with TBST. Next, the membrane was cut at the 50 kDa 
mark to incubate portions with their designated primary antibodies. Membranes were 
probed overnight with either anti-ICAM (Cell Signaling) at a dilution of 1:500 in TBST 
with 1% BSA or anti-GAPDH (Cell Signaling) at a dilution of 1:5000 in TBST with 1% 
BSA. After primary antibody incubation, membranes were washed with TBST 3 times 
for 10 minutes.  A horseradish peroxidase-linked secondary antibody (1:10,000, 
Jackson Labs) was incubated for 2 hours with the designated ICAM-1 (85 kDa) portion 
of the PVDF membrane and 1 hour with the designated GAPDH (37kDa) portion of the 
membrane. For protein detection, SuperSignal™ Chemiluminescent HRP Substrates 
were mixed at a ratio of 1:1. The membrane was then coated and allowed to rest at 
room temperature in solution for 90 seconds. Afterward, the membrane was Saran- 
wrapped and placed in a film cassette.  The film was then exposed in a dark room for 
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various time points and developed with an automated TI-2000 developer. Time of 
exposure was adjusted to allow for visualization of clear bands. ImageJ software was 
used to compare protein levels between groups. GAPDH was utilized as a loading 
control; therefore, resolved ICAM-1 levels were normalized to GAPDH for each group. 
 
 
 
Concentration of Sample Media for VEGF Analysis 
 
Media was collected after the fifth day of treatment and stored at -80°C. Media samples 
were concentrated using 15 mL centrifugal filter spin tubes with a 30 kDa membrane 
(MilliporeSigma,). 10 mL of media was loaded into the spin column.  Tubes were spun 
at 4,000 x g for 10 minutes to reduce sample size to approximately 350 L. 
Concentrated samples were stored at -80°C for future analysis. 
 
 
 
Assessment of VEGF Concentration 
 
Concentrated cell media samples were analyzed using an eBioscience Rat VEGF-C 
Platinum Enzyme-Linked Immunosorbent Assay (ELISA)kit (catalog number BMS626/2) 
and compared to a standard curve. All manufacturer’s protocols were followed while 
performing this assay. A Bioplex Synergy HT plate reader was utilized to measure 
absorbance at 450 nm. 
 
 
 
Statistics 
 
Samples for all assays were conducted in duplicate and averaged. A one-way analysis 
of variance (ANOVA) was used for determining the significant difference between 
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groups. The ANOVA was further followed by a Bonferroni posthoc test. The alpha for 
statistical analysis was set at a p-value of 0.05. 
 
 
IV. RESULTS 
 
Rationale 
 
Therapeutic effects of PBM have been demonstrated in a variety of disorders, primarily 
those in which progression is associated with changes in oxidative stress and 
inflammation. In vitro and in vivo research collectively performed by Tang et al. (2013) 
and Saliba et al. (2015) indicate that, in models of DR, PBM attenuates the 
hyperglycemic induction of oxidative stress and reduces leukostasis (Tang et al. 2013, 
Saliba et al. 2015). The inhibition of leukostasis correlated with a reduction in the 
relative level of ICAM-1. Although PBM has been studied in DR by examination of 
pathological and histological changes, very little is known about the effects of PBM on 
intracellular signaling events. To better understand the mechanism of PBM, we 
designed studies to determine its action on the transcription factor NF-B. Because 
PBM modulates oxidative stress, it is likely that this diminution of oxidative stress will 
diminish the activation of NF-B in a model of DR. The purpose of this experiment is to 
determine the effect PBM on NF-B activity in a Müller glial cell culture model of DR. 
We plan to measure NF-B activity as well as two downstream proteins that are 
transcriptionally regulated by NF-B, ICAM-1 and VEGF (Mamputu et al. 2004, Shelton 
et al. 2007). 
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Part 1. Effects of Photobiomodulation on NF-κB Activity in a Müller glial Cell 
Culture 
 
 
NF-B activity in Müller glial cells cultured in normal (5 mM) glucose or high (25 mM) 
glucose, that were either sham treated or treated with 670 nm LED for 180 seconds at a 
dosage of 4.5 J/cm2 was quantified using a dual luciferase assay. This assay allows for 
a direct measure of NF-B transcriptional activity. When cells were cultured in high 
glucose, there was a significant increase in NF-B activity in comparison to cells 
cultured in normal glucose (n=4, p<0.0001). As shown in Figure 3, a 70% increase in 
luminescence in the high glucose cultured groups was observed in comparison to those 
cultured in normal glucose. To analyze Specific Aim 1, the effects of 670 nm LED 
treatment for 180 seconds at a dosage of 4.5 J/cm2 on Müller cells cultured in high (25 
mM) glucose was additionally analyzed.  After treatment for three days with 670 nm 
LED, the activity of NF-B in high glucose cultures of Müller glial cells was significantly 
reduced (n=4, p<0.0001). As indicated by a p-value of 1 (n=4), there was no statistical 
difference between the degree of NF-B activation in the normal glucose cultured group 
receiving sham treatment in comparison to the high glucose group treated with 670 nm 
PBM. These findings indicate that 670 nm light completely attenuated the activation of 
NF-B induced by hyperglycemia. Furthermore, when cells were cultured in normal 
glucose conditions, treatment with 670 nm light did not appear to affect the activity of 
NF-B (Figure 3). 
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Figure 3: Comparison of NF-κB activity between treatment groups 
Bar graph, representing three separate experiments, showing NF-B activity of 
Müller glial cells maintained in either normal glucose or high glucose medium. 
After three days in culture, cells were collected and lysed for analysis of 
luminescence. Data is presented as a measure of luciferase luminescence 
normalized to Renilla luminescence (transfection control). Results are presented 
as a ratio to activity observed compared to that of the normal glucose, sham- 
treated group. **p<.0001 
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Part 2. Effects of Photobiomodulation on level of ICAM-1 and VEGF 
Concentrations 
 
 
Part 2A: Effects of Photobiomodulation Treatment on ICAM-1 Levels 
 
 
To analyze the effects of high (25 mM) glucose and treatment with 670 nm LED for 180 
seconds at a dosage of 4.5 J/cm2 on the level of ICAM-1 four sets of cells were plated. 
These groups were either cultured in normal (5 mM) glucose or high (25 mM) glucose 
and received either sham or treatment with 670 nm light. After five days of treatment, 
lysates were analyzed by western blot for quantification of ICAM-1. This is longer than 
the time frame used for NF-B activity analysis to provide time for gene transcription 
and protein translation to occur. As shown in Figure 4, we measured an increase in 
ICAM-1 concentrations in cell lysates from cells cultured in high glucose compared to 
those cultured in normal glucose. There was considerable inter-assay variability 
between replicates in our ICAM-1 assays, and our results did not achieve statistical 
significance (n=3, p=.066), likely due to small sample size. We then statistically 
analyzed the effects of 670 nm PBM on the relative level of ICAM-1. Data presented 
shows that PBM-treated cells cultured in high glucose exhibited a decrease in ICAM-1 
levels. We observed a 60% decrease in ICAM-1 concentrations in PBM-treated cells 
cultured in high glucose compared to sham-treated cells cultured in high glucose. 
These differences were not statistically significant (n=3, .089). Each experiment was 
repeated twice. We anticipate that additional experiments will be necessary to observe 
a statistically significant difference. In the high glucose treated cells, ICAM-1 was 
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Figure 4: Comparison of respective ICAM-1 levels between treatment 
groups 
(A) Bar graph, representing three separate experiments, showing the percentage 
of ICAM-1 in relation to GAPDH of Müller glial cells maintained in either normal 
glucose or high glucose medium, which received either PBM or sham treatment. 
Cell lysates were collected from Müller glial cells culture for the analysis of ICAM- 
1 concentrations. Cells either received five days of sham treatment or were 
treated with 670 nm PBM (n=3) (B) Representative Western blot of ICAM-1 and 
GAPDH bands for each treatment group (NS: normal glucose, sham-treated; NT: 
normal glucose, PBM treated; HS: high glucose, sham-treated; HT: high glucose, 
PBM treated). 
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reduced back down to levels comparable to both sham and PBM treated normal 
glucose cultured cells (n=3, p=1). Additionally, between the normal glucose cultured 
group which received 670 nm light and the normal glucose group, which received sham 
treatment there was no significant difference in the relative level of ICAM-1 (n=3, p=1). 
Therefore, in the absence of high glucose treatment with 670 nm LED does not affect 
the level of ICAM-1. 
 
 
 
Part 2B. Effects of 670 nm Photobiomodulation on VEGF concentration in an in vitro 
model of DR. 
 
 
VEGF plays a primary role in the progression of DR. Therefore, the inhibition of VEGF 
signaling has been a primary target for the treatment of DR. To assess the effects of 
670 nm LED on VEGF concentrations, Müller glial cells were cultured in either high or 
normal glucose, with or without 670 nm light treatment. After six days in culture, the 
effect of high glucose on VEGF concentration was analyzed using a sandwich ELISA. 
No significant differences in VEGF levels were observed between high glucose and 
normal glucose medium culture conditions (n=3). Furthermore, 670 nm light treatment 
did not alter VEGF levels in either high glucose conditions or normal glucose conditions. 
Collectively, data presented in Figure 5 indicates that in a cell culture model of Müller 
glial cells, VEGF concentration is not affected by either the concentration of glucose nor 
670 nm light treatment. 
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Figure 5: Comparison of VEGF concentrations between treatment groups 
Bar graph, representing three separate experiments, showing VEGF 
concentration of Müller glial cells maintained in either normal glucose or high 
glucose medium, which received either PBM or sham treated for five days. 
Conditional media was collected from Müller glial for the analysis of VEGF 
concentrations. An ELISA was used for detection of VEGF, and concentrations 
were calculated from a standard curve. 
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V. DISCUSSION 
 
The objective of this thesis study was to determine the effects of 670 nm light in an in 
vitro model of DR. For this investigation, Müller glial cells cultured in high (25 mM) 
glucose received 670 nm light at a dose (or fluence) of 4.5 J/cm2.  To analyze the 
effects of PBM on NF-B transcriptional activity, transfected Müller glial cells were 
cultured under high glucose and were either sham-treated or PBM-treated for three 
days. The data presented shows that treatment with 670 nm LED significantly reduces 
the over-activation of NF-B, which occurred as a consequence of exposure to high 
glucose concentrations. Importantly, NF-B concentrations in PBM-treated high- 
glucose-exposed cultures was not different from that measured in cells maintained 
under normal glucose. Moreover, in comparison to their sham treated, high glucose- 
exposed counterparts, there was a 60% decrease in ICAM-1 concentrations. Our in vitro 
data on the effects of PBM on ICAM-1 concentrations in high glucose cultured Müller 
glial cells was comparable to the in vivo effects of PBM in diabetic rodents (Tang et al. 
2013, Saliba et al. 2015).  Unexpectedly, we observed no change in VEGF 
concentration under high glucose conditions compared to normal glucose cultured cells. 
Furthermore, 670 nm light did not affect VEGF concentrations under either glucose 
condition. Data indicates that in this cell culture model of DR, VEGF is not regulated 
under similar regulatory function as ICAM-1. 
 
 
Although NF-B is known to have diverse regulatory functions, its over-activation has 
shown to be correlated to an increase in oxidative stress and to be of pathological 
significance in animal models of DR (Nagai et al. 2007).  Treatment with 670 nm LED 
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has been assessed in STZ diabetic rat models and shown to attenuate progression and 
improve visual acuity (Tang et al. 2013).  Additionally, PBM decreased oxidative stress 
in both in vivo and in vitro studies of retinal ganglion cells, photoreceptors, retinal 
pigment epithelium cells, and Muller glial cells; which was the cell type also utilized for 
the present study (Tang et al. 2013). How PBM affects intracellular signaling, including 
NF-B transcriptional activity and ICAM-1 or VEGF levels, is addressed in a Müller glial 
cell culture model in this study. 
 
 
Previous in vivo and in vitro studies have demonstrated that a hyperglycemic 
environment induces activation of NF-B. Pericytes cultured in high (30 mM) glucose 
for 8 h, 24 h, 48 h, or 1 week exhibited elevated levels of the NF-B p65 unit in the 
nucleus (Romeo et al. 2002). NF-B concentrations have also been analyzed in retinal 
capillaries of diabetic eye donors removed during the nonproliferative stage of DR 
development (Romero et al. 2002). Results from these studies revealed a greater 
concentration of NF-B inside the nuclei of pericyte cells from diabetic donors in 
comparison to pericytes from non-diabetic donors (Romeo et al. 2002). This indicates 
increased translocation of NF-B to the nucleus, the site where it is functional. 
However, the translocation of NF-B to the nucleus is not necessarily suggestive of 
transcriptional activity (Hayashi et al. 1993). To induce DNA binding and transcriptional 
activity, NF-B must be reduced by redox regulation (Hayashi et al. 1993). In our study, 
a 70% increase in NF-B transcriptional activity in the high glucose cultured, sham 
treated groups was observed in comparison to cells cultured in normal glucose and not 
receiving treatment (Figure 3). These findings support previous work by Shelton et al. 
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(2007) and Shanmugam et al. (2003). Shelton et al. reported elevated NF-B activity in 
transfected Müller glial cells after 8 hours in high glucose (25 mmol/L) in comparison to 
cells maintained in normal glucose (Shelton et al. 2007). In accordance with this data, 
transfected THP-1 (human leukemic monocytes) cells incubated under high glucose for 
three days presented with a five-fold increase in NF-B activity in comparison to those 
cultured in normal glucose (Shanmugam et al. 2003).  However, not all cell types 
appear to follow this pattern. Endothelial cells cultured in high (30 mM) glucose for 8 
hrs, 24 hrs, 72 hrs, and one week had no significant difference in the translocation of 
NF-B to the nucleus when compared to cells cultured in normal glucose culture media 
(Romeo et al. 2002). These results suggest that the translocation of NF-B to the 
nucleus in response to high glucose appears to be cell type specific. 
 
 
In addition to the observed increase in NF-B, ICAM-1 levels were also elevated when 
Müller glial cells were cultured in high (25 mM) glucose conditions. We measured 
ICAM-1 levels by Western blot on samples treated for five days, based on a prior study 
by Chen et al. (2012) observing elevated levels of ICAM-1 when cells were cultured in 
high glucose for a range of one to seven days (Chen et al. 2012). After six days in high 
glucose conditions, a two-fold increase in ICAM-1 concentration relative to levels of 
GAPDH was observed (Figure 4). Our findings are in agreement with previous studies. 
Elevated levels of ICAM-1 were, as well, observed in STZ diabetic mice in comparison 
to non-diabetic control animals (Tang et al. 2013, Elmarakby et al. 2012). Likewise, in a 
Müller glial cell culture model of DR, a 4-fold increase in ICAM-1 levels was reported for 
cells cultured in high (25 mM) glucose in comparison to cells cultured in normal glucose 
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conditions for five days. Unlike prior studies, our data did not reach significance; 
however, conducting additional experiments or measuring membrane bound ICAM-1 
rather than total protein concentration might enable us to achieve statistically significant 
changes. Since ICAM-1 induces its function when membrane bound, this may provide a 
better measure of biological significance. 
 
 
We postulate that the induction of NF-B activity, and the increase in ICAM-1 
concentrations, observed in the present study as a result of high glucose exposure 
occurs due to an increase in oxidative stress based on the effects of antioxidants in 
models of DR (Kowluru et al. 2003). Two months post-induction of diabetes in STZ 
diabetic rats the activation of NF-B was increased by 60% in retinal samples compared 
to non-diabetic counterparts (Kowluru et al. 2003). Corresponding to this increase in 
NF-B activity was a reduction in the antioxidant capacity of superoxide dismutase and 
an increase in oxidative stress, as measured by the presence of 8-isoprostane in the 
blood and ratio of oxidized glutathione to reduced glutathione (Kowluru et al. 2003). 
The increase in NF-B activity and oxidative stress, as well as the reduction in 
antioxidant capacity of superoxide dismutase, was partially attenuated in diabetic rats 
which were treated with the antioxidant resveratrol (Kowluru et al. 2003). Thus, it is 
likely that the observed increase in transcriptional activity may be related to a 
hyperglycemic induction in oxidative stress (Kowluru et al. 2003, Kim et al. 2007). 
 
 
In the progression of DR, the induction of ICAM-1, as a result of NF-B activation 
induced by oxidative stress, promotes the movement of leukocytes (leukostasis) and 
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subsequent death of endothelial cells (Kowluru et al. 2003, Joussen et al. 2001). 
Therefore, inhibition of NF-B, directly or indirectly, may provide a means in which to 
control the progression of DR. As discussed, one manner in which NF-B activity can 
be modulated is through the reduction of oxidative stress (Kowluru et al. 2003). In a 
multitude of models, treatment with light in the NIR range has been shown to diminish 
oxidative stress (Tang et al. 2013, Saliba et al. 2015, Silva Macedo et al. 2015, 
Purushothuham et al. 2014). Tang et al. (2013) determined the effects of PBM on 
oxidative stress in various cell cultures models of DR. For these studies, retinal glial 
cells, photoreceptors, Müller glial cells, and retinal pigment epithelial cells were 
maintained in 30 mmol/L glucose (Tang et al. 2013). For cells cultured in high (30 mM) 
glucose, there was a significant increase in oxidative stress, as indicated by the 
presence of superoxide when compared to cells cultured in normal (5 mM) glucose 
media (Tang et al. 2013). The effects of hyperglycemic conditions were ameliorated in 
groups receiving 670 nm LED treatment for four days at a dosage of 5 J/cm2 (Tang et 
al. 2013). 
 
 
In STZ-diabetic rats, light treatment was performed at the early onset of DR (7 to 10 
days post STZ administration). Animals received 670 nm LED treatment once daily at 
an irradiance of 25 mW/cm2 for 270 seconds producing a dose 6.8 J/cm2 for nine 
weeks. Treatment with 670 nm LED resulted in decreased superoxide levels in the 
retina in comparison to non-diabetic controls (Tang et al. 2013). Similarly, diabetic mice 
presented with an increase in retinal superoxide concentrations in comparison to non- 
diabetic animals, which coincided with enhanced leukostasis and elevated ICAM-1 
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concentrations within the retinae of diabetic animals (Tang et al. 2013). Subsequent 
studies by Saliba et al. (2015) observed similar results to those presented by Tang et al. 
(2013). Animals were either sham treated or were treated with 670 nm LED for ten 
weeks at a daily dosage of 5 J/cm2 (Saliba et al. 2015). They observed an increase in 
leukostasis, superoxide, and ICAM-1 levels in diabetic mice when compared to non- 
diabetic control mice. The increase in leukostasis, superoxide, and ICAM-1 induced by 
diabetes was ameliorated in groups treated with 670 nm LED (Saliba et al. 2015). 
Additionally, these animals had an improvement in retinal function as measured by 
ERGs (Saliba et al. 2015). Collectively, this data indicates that PBM attenuates 
oxidative stress, which corresponds to an alleviation of leukostasis as a result of 
decreased ICAM-1 concentrations. Due to the relationship between oxidative stress, 
NF-B, and ICAM-1 in the development of DR, it was likely that this treatment would 
promote similar effects on NF-B activity. 
 
 
To test this, we cultured Müller glial cells under high (25 mM) glucose conditions and 
then treated the cells with 670 nm LED at a dosage of 4.5 J/cm2, or sham treated, for 
three days. Treatment with 670 nm LED promoted a significant reduction in NF-B 
activity and a reduction of ICAM-1 levels in a cell culture of Müller glial cells. As 
mentioned earlier, it is suspected that these observations occur as a result of a 
reduction in oxidative stress, as shown by Tang et al. (2013) and Saliba et al. (2015). 
This theory is supported by work performed by Shelton et al. (2007). Under 
homeostasis, glutaredoxin is considered protective and functions to prevent the 
irreversible oxidation of proteins.  However, in diseases with unresolving oxidative 
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stress, such as DR, enhanced glutaredoxin activity may disrupt normal redox regulation 
of transcription factors including NF-B. Such a state has been observed in Müller glial 
cells incubated in high glucose (Shelton et al. 2007). In Müller glial cells cultured in high 
glucose, there was a notable increase in glutaredoxin activity, NF-B transcriptional 
activity, and an increase in ICAM-1 levels (Shelton et al. 2007). Additionally, when 
glutaredoxin was overexpressed, there was an increase in the nuclear localization of 
NF-B (Shelton et al. 2007) Conversely, when glutaredoxin activity was knocked down 
in high glucose cultured Müller cells, there was a significant decrease in ICAM-1 
(Shelton et al. 2007). These results suggest that the hyperglycemic induction of 
oxidative stress enhances the glutaredoxin redox regulation of NF-B. Attenuation of 
this oxidative stress by PBM, as presented by Tang et al., could diminish the redox 
activity of glutaredoxin and, correspondingly, abate the increased activity of NF-B, 
such as that observed in this study (Tang et al. 2013). However, since oxidative stress 
was not directly measured in the current study, further work is needed to compare the 
effects of PBM on oxidative stress, NF-B, and ICAM-1. 
 
 
In regards to prior work performed assessing the effects of PBM on the activity of NF- 
 
B, results presented both in this study and prior studies remain inconclusive. In a 
model of burn wound healing 904 nm light modulated the activation of NF-B as 
measured by western blot (Gupta et al. 2015). The injury was induced on Sprague- 
Dawley rats by an aluminum metal rod heated to 85°C (Gupta et al. 2015). Sprague- 
Dawley rats received treatment for seven days for a duration of 3, 10, or 15 minutes 
with 904 nm light, or received sham treatment (Gupta et al. 2015).  NF-B activity was 
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significantly reduced for injured animals, which received treatment with 904 nm light in 
comparison to their sham treated counterparts (Mafra de Lima et al. 2009). Conversely, 
in a model of airway inflammation treatment with PBM increased the activity of NF-B 
(Mafra de Lima et al. 2009). Airway inflammation was induced in bronchi isolated from 
male Wistar rats. The bronchi were treated with 650 nm light twice daily for 42 seconds 
at a dosage of 1.3 J/cm2 (Mafra de Lima et al. 2009). Treatment with 650 nm light 
reduced constriction to the bronchi when airway inflammation was induced. However, 
when and NF-B inhibitors were introduced the beneficial effects of 650 nm light was 
attenuated. These results suggest that NF-B activation by PBM is important for 
therapeutic effects (Mafra de Lima et al. 2009).  However, due to the diverse role of NF- 
B in maintaining cellular function, as well as varying effects observed between 
wavelengths and dosages further work is needed to better understand the effect of PBM 
on NF-B in varying models. 
 
 
Unexpectedly, we observed that high glucose culture conditions did not significantly 
alter VEGF concentrations compared to Müller glial cells cultured in normal (5 mM) 
glucose conditions (data representative of three independent experiments). We were 
surprised that VEGF was not increased by high glucose in Müller cells, as this does not 
compare with observations reported by previous studies. Bai et al. (2009) have 
suggested that Müller glial cells are primarily responsible for the increase in VEGF 
observed in animal models of DR.  In conditional VEGF knockout mice, a Cre/lox 
system was used to determine the significance of Müller glial cell-derived VEGF. When 
VEGF synthesis was blocked in Müller glial cells of the conditional mice, a 44.5% 
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decrease in VEGF retinal concentration was observed in comparison to their WT 
counterparts (Bai et al. 2009). However, these results also indicate that more than 50% 
of VEGF is attributed to additional sources, including neuronal cells and RPE cells. 
Therefore, a pure Müller cell culture system may not provide substantial concentrations 
of VEGF to analyze the effect of 670 nm LED treatment. Analysis of VEGF 
concentrations in aqueous humor samples from diabetic patients, without PDR, 
revealed very low concentrations of this growth factor, suggesting that it may be 
challenging to measure VEGF changes above baseline levels (Oh et al. 2010). 
Comparison of VEGF concentrations in the aqueous humor, as well, presented no 
significant difference between samples collected from non-diabetics, diabetics, or 
diabetics with severe non-proliferative DR (Oh et al. 2010). It was not until patients had 
developed PDR that a significant increase in VEGF concentration was observed. The 
difference in VEGF concentration observed between patients with non-proliferative DR 
and PDR was 30 pg/mL (Oh et al. 2010). Therefore, based on findings by Bai et al. 
(2009), only half of the change in concentration was a result of Müller glial cells (Bai et 
al. 2009, Oh et al. 2010). Therefore, our model may not be representative of PDR. The 
changes in the concentration of VEGF may also not be great enough above baseline to 
determine statistical differences. 
 
 
Differences between cell culture models and time points selected for analysis may 
account for the variability observed between our results and previous findings in animals 
and other cell culture models. For instance, Natarajan et al. (1997) cultured primary 
vascular smooth muscle cells in high glucose (25 mmol/L) and normal glucose (5 
51  
mmol/L). Each group of cells were cultured for two passages under selected conditions, 
and then a northern blot was performed for detection of VEGF mRNA (Natarajan et al. 
1997). High glucose conditions resulted in a 2.5-fold increase in VEGF mRNA in 
comparison to cells cultured in normal glucose conditions (Natarajan et al. 1997). In 
primary rMC cultured in high glucose (30 mmol/L), both protein and mRNA levels of 
VEGF were increased at the time points of 8 hrs, 12 hrs, and 24 hrs (Ya et al. 2012). 
However, levels of VEGF in primary rMC decreased from 24 to 48 hours (Ya et al. 
 
2012).  Therefore, we may have missed the time point at which VEGF is elevated. 
 
 
 
 
Contrary to these studies, Brooks et al. suggest that high glucose alone may not 
effectively induce VEGF synthesis in Müller glial cells (Brooks et al. 2005). Brooks et al. 
(2005) analyzed the effects of pH and glucose on VEGF production under normoxic and 
hypoxic conditions. After 48 hours, it was observed that when cells were cultured under 
hypoxic conditions both glucose and pH had a significant effect on VEGF production 
(Brooks et al. 2005).  However, if cells were cultured in normoxic conditions for 48 
hours, pH and glucose had no measurable effect on VEGF synthesis (Brooks et al. 
2005). 
 
 
 
 
Comparison of Ya et al. (2012) and Brooks et al. (2005) protocols indicate two 
differences, time course of experiments and serum presence. In work performed by 
Natarajan et al. (1997), and Ya et al. (2012) media was supplemented with 0.2% BSA or 
0.5% BSA, respectively. In our study and Brooks et al. medium was supplemented with 
2% FBS and 10% FBS, respectively.  In these studies, hyperglycemia alone was not 
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found to induce VEGF (Brooks et al. 2005). Both of these serum supplements may 
contain constitutive growth factors, which could affect results of the assays. FBS, in 
particular, may contain growth factors unfavorable for analysis of VEGF. In a cell culture 
of dermal fibroblasts, 10% FBS was found to upregulate expression of pigment 
epithelium-derived factor, which is known to inhibit the synthesis of VEGF (Man et al. 
2009, Zhang et al. 2006). Differences in serum type and serum concentrations could 
account for the observable difference. In addition to differences in serum, the time 
course utilized varied among the studies. A time course analysis, as well as, studies 
analyzing differences between culture conditions may help clarify the variability 
observed between the current and prior studies. 
 
 
Our experimental design also allowed us to examine PBM effects in the presence of 
normal glucose levels. We show that PBM has no effect on NF-B or ICAM-1 levels in 
cells cultured in normal glucose medium (Figure 3 and 4). This suggests that, in the 
absence of high glucose, PBM does not have an impact on NF-B transcriptional 
activity and relative level of ICAM-1. Thus, in regards to DR, treatment with 670 nm 
LED may only have certain effects while in a hyperglycemic state. 
 
 
Taken together, we show that 670 nm LED treatment may provide therapeutic effects in 
models of DR by reducing the increase in NF-B transcriptional activity and the increase 
in the level of ICAM-1 induced by high glucose culture conditions. Further research 
utilizing animal models will help develop an understanding of the effects PBM has on 
intracellular signaling.  As mentioned, signaling through the AGE-RAGE pathway also 
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plays a role in the development and progression of DR. Animal studies will also allow 
for the analyzation of treatment with 670 nm LED in advanced stages of DR, and 
confirm if this treatment will have the same effect on transcriptional activity of NF-B 
and changes in the level of ICAM-1. 
 
 
 
Conclusion and Future Directions 
 
The aim of this study was to determine the effects PBM using 670 nm light for 180 
seconds on the activity of NF-B, as well as its effects on concentrations of ICAM-1 and 
VEGF. The hypothesis for this study was that 670 nm light will attenuate the 
hyperglycemic induction of NF-B and reduce the concentrations of ICAM-1 and VEGF 
in a Müller glial cell culture. The data presented in this thesis partially supports the 
central hypothesis. Data showed that in the presence of high glucose 670 nm light 
treatment significantly reduced NF-B activity. Similar results were also obtained for 
ICAM-1. When Müller glial cells cultured in high glucose were treated for five days with 
670 nm LED the level of ICAM-1 detected was 60% lower than that observed in high 
glucose cultured cells receiving sham treatment. We also analyzed the effects of PBM 
on NF-B and ICAM-1 when cells were cultured under normal conditions. Between 
normal glucose cultured groups, which received 670 nm light treatment and those which 
did not, there was not a significant difference in either transcriptional activity of NF-B or 
the level of ICAM-1.  Further studies are needed to support these findings due to ICAM- 
1 analysis not reaching statistical differences. Performing a time course study for both 
ICAM-1 and NF-B would also better allow a direct comparison of the transcriptional 
activity of NF-B to the synthesis of ICAM-1. 
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Currently, our data indicate that VEGF may not be regulated by NF-B in our model 
system. However, cell culture analysis for the effects of high glucose on VEGF in 
previous studies suggests contradictory findings to the data presented (Ya et al. 2012, 
Brooks et al. 2005). As suggested above, adjustments to time course and culture 
conditions may be needed to be made for further VEGF studies. 
 
 
Translation into an animal model may also provide the best manner in which to study 
the effects of DR. Performing these experiments in an animal model will allow for 
examination of changes in the retina, where multiple cell types are present, and cell-cell 
contact and paracrine signaling may take place. To do this, the treatment protocol (240 
seconds daily, 25 mW/cm2, 6 J/ cm2) previously established by Tang et al. (2013) would 
be followed, since therapeutic effects, as indicated in improvements in retinal function, 
have been previously established. Changes in NF-B translocation would be measure 
from excised retina samples. Furthermore, ICAM-1 and VEGF concentrations can be 
measured by an immunoprecipitation assay as described in Tang et al. (Tang et al. 
2013). Addition of a NF-B inhibitor would also provide a manner to confirm the relation 
between NF-B and ICAM-1 in a model of DR. 
 
 
In conclusion, the work presented in this study does support that treatment with 670 nm 
light has an inhibitory effect on NF-B and reduces the synthesis of ICAM-1. This work 
has begun to provide a mechanism of action for treatment with 670 nm light in our 
model system.  Examining the role of NF-B with and without PBM in an animal will 
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allow for further mechanistic insight into PBM. Further elucidation of the mechanism of 
action for 670 nm light treatment in a model of DR, will assist in the movement of PBM 
therapy to clinical use. 
56  
REFERENCES 
 
Agrawal, T.; et al. “Pre-condition with low-level laser (light) therapy: light before the 
storm.” Dose-Response 12.4 (2014). 
Al-Watban, F., and G.D. Delgado. "Burn healing with a diode laser: 670 nm at different 
doses as compared to a placebo group." Photomedicine and Laser Therapy 23.3 
(2005): 245-250. 
Amano, Shinjiro, et al. "Pigment epithelium-derived factor inhibits oxidative stress- 
induced apoptosis and dysfunction of cultured retinal pericytes." Microvascular 
Research 69.1 (2005): 45-55. 
Aubert, C. E., et al. "Association of peripheral neuropathy with circulating advanced 
glycation end products, soluble receptor for advanced glycation end products and 
other risk factors in patients with type 2 diabetes." Diabetes/Metabolism 
Research and Reviews 30.8 (2014): 679-685. 
Bai, Yanyan, et al. "Müller cell‐derived VEGF is a significant contributor to retinal 
neovascularization." The Journal of Pathology 219.4 (2009): 446-454. 
Ball, K.A, P.R. Catello, R.O Poyton “Low intensity light stimulates nitrite-dependent nitric 
oxide synthesis but not oxygen consumption by cytochrome c oxidase: 
implications for phototherapy. Journal of Photochemistry and Photobiology B 102 
(2011): 182-191. 
Begum, Rana, et al. "Treatment with 670 nm light upregulates cytochrome C oxidase 
expression and reduces inflammation in an age-related macular degeneration 
model." PloS one 8.2 (2013): e57828. 
57  
Brown, Adrienne M., et al. "Function of NF-kappa B/Rel binding sites in the major 
histocompatibility complex class II invariant chain promoter is dependent on cell- 
specific binding of different NF-kappa B/Rel subunits." Molecular and Cellular 
Biology 14.5 (1994): 2926-2935. 
Centers for Disease Control and Prevention. “Diabetic Retinopathy.” Atlanta, GA: US 
Department of Health and Human Services; 2008 
Centers for Disease Control and Prevention. “National diabetes statistics report: 
estimates of diabetes and its burden in the United States.” Atlanta, GA: US 
Department of Health and Human Services; 2014. 
Cervellati, F., et al. “Hypoxia induces cell damage via oxidative stress in retinal epithelial 
cells.” Free Radical Research 48.3 (2014): 303-312. 
Chen, J., et al. "Ginkgo biloba extract reduces high-glucose-induced endothelial 
adhesion by inhibiting the redox-dependent interleukin-6 pathways." 
Cardiovascular diabetology 11.49 (2012). 
Cummins, Nadia, et al. "Changes to mitochondrial ultrastructure in optic nerve 
vulnerable to secondary degeneration in vivo are limited by irradiation at 670 
nm." BMC Neuroscience 14.1 (2013). 
Demontic, G.C., B. Longoni, and P.L. Marchiafava. “Molecular steps involved in light- 
induced oxidative damage to retinal rods” Journal of Investigative Ophthalmology 
and Visual Science 43 (2002): 2421-2427. 
Eells, J. T., et al. "Therapeutic photobiomodulation for methanol-induced retinal toxicity." 
 
Proceedings of the National Academy of Sciences 100.6 (2003): 3439-3444. 
58  
Elmarakby, Ahmed A., and Jennifer C. Sullivan. "Relationship between oxidative stress 
and inflammatory cytokines in diabetic nephropathy." Cardiovascular 
Therapeutics 30.1 (2012): 49-59. 
Fong, C., et al. “An anti-inflammatory role for IKKβ through the inhibition of “classical” 
macrophage activation.” The Journal of Experimental Medicine 205.6 (2008): 
1269-1276. 
Frydkjaer-Olsen, Ulrik, et al. "Retinal Vascular Fractals Correlate With Early 
Neurodegeneration in Patients With Type 2 Diabetes MellitusEarly Vascular and 
Neurogenic Changes in Diabetes." Investigative Ophthalmology & Visual 
Science 56.12 (2015): 7438-7443. 
Fuma, S.; et al. “Photobiomodulation with 670 nm light increased phagocytosis in 
human retinal pigment epithelial cells.” Molecular vision 21 (2015): 883. 
Gaida, K.; et al. “Low-Level Laser Therapy—a conservative approach to the burn scar.” 
Burns 30.4 (2004): 362-367. 
Geraldes, P.; et al. “Activation of PKC-δ and SHP-1 by hyperglycemia causes vascular 
cell apoptosis and diabetic retinopathy.” Nature Medicine (2009): 1298-1306. 
Gerhardinger, C., et al. "Expression of acute-phase response proteins in retinal Muller 
cells in diabetes." Investigative Ophthalmology & Visual Science 46.1 (2005): 
349-357. 
Gupta, A., et al. “Superpulsed (Ga-As, 904 nm) low-level laser therapy (LLLT) 
attenuates inflammatory response and enhances healing of burn wounds.” 
Journal of Biophotonics 8.6 (2015): 489-501. 
59  
Ghose, J. and Bhattacharyya, N.P. “Transcriptional regulation of microRNA-100, -146a, 
and -150 genes by p53 and NFkB p65/RelA in mouse striatal STHdhQ7/HdhQ7 
cells and human cervical carcinoma HeLa cells.” RNA Biology 12.4 (2015): 457- 
477. 
Harada, C., et al. "Role of monocyte chemotactic protein-1 and nuclear factor kappa B 
in the pathogenesis of proliferative diabetic retinopathy." Diabetes Research and 
Clinical Practice 74.3 (2006): 249-256. 
Hayashi, T., Y. Ueno, and T. Okamoto. "Oxidoreductive regulation of nuclear factor 
kappa B. Involvement of a cellular reducing catalyst thioredoxin." Journal of 
Biological Chemistry 268.15 (1993): 11380-11388. 
Hodgson, B.D., et al. “Amelioration of oral mucositis pain by NASA near-infrared light- 
emitting diodes in bone marrow transplant patients.” Supportive Care in Cancer 
20.7 (2012): 1405-1415. 
Huang, Y., et al. Low-Level laser therapy (LLLT) reduces oxidative stress in primary 
cortical neurons in vitro.” Journal of Biophotonics 6.10 (2013): 829. 
Hu, Y., et al. “Duration of obesity and overweight and risk of type 2 diabetes among US 
women.” Obesity 22.10 (2014): 2267-2273. 
Jo, D.H., et al. "Interaction between pericytes and endothelial cells leads to formation of 
tight junction in hyaloid vessels." Molecules and Cells 36.5 (2013): 465-471. 
Jonsson, K.B., U. Frydkjaer-Olsen, and J. Grauslund. "Vascular changes and 
neurodegeneration in the early stages of diabetic retinopathy: which comes 
first?." Ophthalmic Research 56.1 (2016): 1-9. 
60  
Joussen, A.; et al. “Leukocyte-mediated endothelial cell injury and death in the diabetic 
retina.” The American Journal of Pathology 158.1 (2001): 147-152. 
Kanwar, M.; et al. "Role of glyceraldehyde 3-phosphate dehydrogenase in the 
development and progression of diabetic retinopathy." Diabetes 58.1 (2009): 
227-234. 
Kim, L.; et al. “Characterization of cells from patient-derived fibrovascular membranes in 
proliferative diabetic retinopathy.” Molecular Vision 12.21 (2015): 673-687. 
Kim, S.; et al. “Assessment of glycemic control in patients with type 2 diabetes mellitus 
treated with metformin-sulfonylurea combination: Results of a multicenter, cross- 
sectional, observational study in Korea.” Journal of Diabetes Investigation 6.3 
(2015): 317-324. 
Kim, S., et al. "Visfatin enhances ICAM-1 and VCAM-1 expression through ROS- 
dependent NF-κB activation in endothelial cells." Biochimica et Biophysica Acta 
(BBA)-Molecular Cell Research 1783.5 (2008): 886-895. 
Kim, Y.; et al. “Curcumin attenuates inflammatory responses of TNF-α-stimulated 
human endothelial cells.” Journal of Cardiovascular Pharmacology 50.1 (2007): 
41-49. 
Kirk, D. K., et al. "Photobiomodulation reduces photoreceptor death and regulates 
cytoprotection in early states of P23H retinal dystrophy." SPIE BiOS. 
International Society for Optics and Photonics (2013). 
Kowluru, R. "Diabetes-induced elevations in retinal oxidative stress, protein kinase C 
and nitric oxide are interrelated." Acta Diabetologica 38.4 (2001): 179-185. 
61  
Kowluru, R. A., L. Atasi, and Y. Ho. "Role of mitochondrial superoxide dismutase in the 
development of diabetic retinopathy." Investigative Ophthalmology & Visual 
Science 47.4 (2006): 1594-1599. 
Lampl, Y., et al. “Infrared laser therapy for ischemic stroke: a new treatment strategy: 
results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1)” Stroke 38.6 
(2007): 1843-1849. 
Lennikov, A., et al. "IκB kinase-β inhibitor IMD-0354 beneficially suppresses retinal 
vascular permeability in streptozotocin-induced diabetic mice IMD-0354 
suppresses retinal vascular permeability." Investigative Ophthalmology & Visual 
Science 55.10 (2014): 6365-6373. 
Li, J.; et al. “KB-R7943 inhibits high glucose-induced endothelial ICAM-1 expression 
and monocyte endothelial adhesion.” Biochemical and Biophysical Research 
Communications 392.4 (2010): 516-519. 
Liu, B.; et al. “Proinflammatory stimuli induce IKKα-mediated phosphorylation of PIAS1 
to restrict inflammation and immunity.” Cell 129.5 (2007): 903-914. 
Liu, Y.; et al. “Glycemic exposure and blood pressure influencing progression and 
remission of diabetic retinopathy: a longitudinal cohort study in GoDARTS.” 
Diabetes Care 36.12 (2013): 3979-3984. 
Lohr, Nicole L., et al. "Enhancement of nitric oxide release from nitrosyl hemoglobin and 
nitrosyl myoglobin by red/near infrared radiation: potential role in 
cardioprotection." Journal of Molecular and Cellular Cardiology 47.2 (2009): 256- 
263. 
62  
Machida, S., et al. “P23H rhodopsin transgenic: correlation of retinal function with 
histopathology.” Investigative Ophthalmology & Visual Science 41.10 (2000): 
3200-3209. 
Mafra de Lima, F.; et al. "Low-level laser therapy (LLLT): Attenuation of cholinergic 
hyperreactivity, β2‐adrenergic hyporesponsiveness and TNF‐α mRNA expression 
in rat bronchi segments in E. coli lipopolysaccharide‐induced airway inflammation 
by a NF‐κB dependent mechanism." Lasers in Surgery and Medicine 41.1 
(2009): 68-74. 
Maleki, S.; et al. “Optical imaging of mitochondrial redox state in rodent model of retinitis 
pigmentosa.” Journal of Biomedical Optics 18.1 (2013): 016004-016004. 
Mamputu, J.; et al. “Advance glycation end-products increase monocyte adhesion to 
retinal endothelial cells through vascular endothelial growth factor induces ICAM- 
1 expression; inhibitory effects of antioxidants.” Journal of Leukocyte Biology 
75.6 (2004): 1062-1069. 
Man, X., et al. "Fetal bovine serum enhances expression of PEDF in epidermal 
keratinocytes and dermal fibroblasts." Journal of Zhejiang University Medical 
Sciences 38.4 (2009): 343-347. 
Marshall, J.; et al. “Inhibition of N-methyl-D-aspartate-induced retinal neuronal death by 
polyarginine peptides is linked to the attenuation of stress-induced 
hyperpolarization of the inner mitochondrial membrane potential.” Journal of 
Biological Chemistry 290.36 (2015): 22030-22048. 
63  
Melotti, P., et al. "Activation of NF-kB mediates ICAM-1 induction in respiratory cells 
exposed to an adenovirus-derived vector." Gene Therapy 8.18 (2001): 1436- 
1442. 
Merry, G., et al. "Treatment of dry age-related-macular degeneration with 
photobiomodulation." Proceedings of the 9th WALT Congress. Medimond, 
Bologna, 2013. 
Montoro, L.A.; et al. “Infrared LED irradiation photobiomodulation of oxidative stress in 
human dental pulp cells.” International Endodontic Journal 47.8 (2014): 747-755. 
Nagai, N.; et al. “Suppression of diabetes-induced retinal inflammation by blocking the 
angiotensin II type 1 receptor or its downstream nuclear factor κB pathway.” 
Investigative Ophthalmology and Visual Science 48.9 (2007): 4342-4350. 
Natarajan, R., et al. "Effects of high glucose on vascular endothelial growth factor 
expression in vascular smooth muscle cells." American Journal of Physiology- 
Heart and Circulatory Physiology 273.5 (1997): H2224-H2231. 
Natasja, K.; et al. “Circulating forms of intercellular adhesion molecule (ICAM)-1 in mice 
lacking membranous ICAM-1.” Blood 95.4 (2000): 1350-1355. 
Nayak, J.; et al. “Automated Identification of Diabetic Retinopathy Stages Using Digital 
Fundus Images.” Journal of Medical Systems 32.2 (2007): 107-115. 
Obrosova, I. G., et al. "Antioxidants attenuate early up-regulation of retinal vascular 
endothelial growth factor in streptozotocin-diabetic rats." Diabetologia 44.9 
(2001): 1102-1110. 
Peppiatt, C. M., et al. "Bidirectional control of CNS capillary diameter by 
pericytes." Nature 443.7112 (2006): 700-704. 
64  
Pinto, N.; et al. “Low level laser therapy in acute dehiscence saphenectomy: therapeutic 
proposal.” Revista Brasileira de Cirurgia Cardiovascular 24.1 (2009): 88-91. 
Preti, R.C., et al. "Single intravitreal bevacizumab injection effects on contrast sensitivity 
in macular edema from branch retinal vein occlusion." Arquivos Brasileiros de 
Oftalmologia 75.1 (2012): 29-32. 
Purushothuman, S., et al. "Photobiomodulation with near infrared light mitigates 
Alzheimer’s disease-related pathology in cerebral cortex–evidence from two 
transgenic mouse models." Alzheimer's Research & Therapy 6.1 (2014): 1. 
Romeo, G., et al. "Activation of nuclear factor-κB induced by diabetes and high glucose 
regulates a proapoptotic program in retinal pericytes." Diabetes 51.7 (2002): 
2241-2248. 
Saliba, A.; et al. “Photobiomodulation mitigates diabetes-induced retinopathy by direct 
and indirect mechanisms: Evidence from intervention studies in pigmented mice.” 
PLoS One 10.10 (2015): e0139003. 
Shanmugam, N., et al. "High glucose-induced expression of proinflammatory cytokine 
and chemokine genes in monocytic cells." Diabetes 52.5 (2003): 1256-1264. 
Shelton, M.; et al. “Glutaredoxin regulates nuclear factor κ-B and intercellular adhesion 
molecule in Müller Cells: model of diabetic retinopathy.” Journal of Biological 
Chemistry 282.17 (2007): 12467-12474. 
Severin, F.; et al. "Advanced glycation of cellular proteins as a possible basic 
component of the “master biological clock.” Biochemistry (Moscow) 78.9 (2013): 
1043-1047. 
65  
Shen, Weiyong, et al. "Conditional Müller cell ablation causes independent neuronal 
and vascular pathologies in a novel transgenic model." The Journal of 
Neuroscience 32.45 (2012): 15715-15727. 
Sher, A.; et al. “Restoration of Retinal Structure and Function after Selective 
Photocoagulation.” Journal of Neuroscience 33.16 (2013) 6800-6808. 
Shin, Y.; et al. “Effects of intravitreal bevacizumab injection combined with panretinal 
photocoagulation on high-risk proliferative diabetic retinopathy.” Korean Journal 
of Ophthalmology 23.4 (2009) 266-272. 
Silva Macedo, R., et al. "Photobiomodulation Therapy Decreases Oxidative Stress in 
the Lung Tissue after Formaldehyde Exposure: Role of Oxidant/Antioxidant 
Enzymes." Mediators of Inflammation 2016 (2016). 
Song, S., et al. "cDNA microarray analysis of gene expression profiles in human 
fibroblast cells irradiated with red light." Journal of Investigative Dermatology 
120.5 (2003): 849-857. 
Soufi, F.; et al. “Resveratrol improves diabetic retinopathy possibly through oxidative 
stress – nuclear factor κB – apoptosis pathway.” Pharmacological Reports 64.6 
(2012): 1505-1514. 
Tang, J.; et al. “Low-intensity far-red light inhibits early lesions that contribute to diabetic 
retinopathy: in vivo and in vitro.” Investigative Ophthalmology and Visual Science 
54.5 (2013) 3681. 
Tang, J. et al. “Photobiomodulation in the treatment of patients with non-center-involving 
diabetic macular edema.” British Journal of Ophthalmology 98.8 (2014): 1013- 
1015. 
66  
Trudeau, K., et al. "High glucose disrupts mitochondrial morphology in retinal 
endothelial cells: implications for diabetic retinopathy." The American Journal of 
Pathology 177.1 (2010): 447-455. 
Wang, J.; et al. "Müller cell-derived VEGF is essential for diabetes-induced retinal 
inflammation and vascular leakage." Diabetes 59.9 (2010): 2297-2305. 
Wautier, J. L., et al. "Advanced glycation end products (AGEs) on the surface of diabetic 
erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress 
in the vasculature: a link between surface-associated AGEs and diabetic 
complications." Proceedings of the National Academy of Sciences 91.16 (1994): 
7742-7746. 
Wendt, T. M., et al. "RAGE drives the development of glomerulosclerosis and implicates 
podocyte activation in the pathogenesis of diabetic nephropathy." The American 
Journal of Pathology 162.4 (2003): 1123-1137. 
Werner, S. L., D. Barken, and A. Hoffmann. "Stimulus specificity of gene expression 
programs determined by temporal control of IKK activity." Science 309.5742 
(2005): 1857-1861. 
Whelan, H.T.; et al. “NASA light-emitting diodes for the prevention of oral mucositis in 
pediatric bone marrow transplant patients.” Journal of Clinical Laser Medicine & 
Surgery 20.6 (2002): 319-324. 
Wong, J.; et al. “Timing is Everything: Age of Onset Influences Long-Term Retinopathy 
Risk in Type 2 Diabetes, Independent of Traditional Risk Factors.” Diabetes Care 
31.10 (2008): 1985-1990. 
67  
Wong-Riley, M.; et al. “Photobiomodulation Directly Benefits Primary Neurons 
Functionally Inactivated by Toxins: Role of Cytochrome C Oxidase.” The Journal 
of Biological Chemistry 280.6 (2005): 4761-4771. 
Wu, Li., and B. Juurlink. "Increased methylglyoxal and oxidative stress in hypertensive 
rat vascular smooth muscle cells." Hypertension 39.3 (2002): 809-814. 
Wu, Q., et al. "Low‐level laser therapy for closed‐head traumatic brain injury in mice: 
 
effect of different wavelengths." Lasers in Surgery and Medicine 44.3 (2012): 
218-226. 
Xia, P., et al. "Characterization of the mechanism for the chronic activation of 
diacylglycerol-protein kinase C pathway in diabetes and 
hypergalactosemia." Diabetes 43.9 (1994): 1122-1129 
Yamaguchi S., H.S. Katahira, Ozawa S, et. al. “Activators of AMP-activated protein 
kinase enhance GLUT4 translocation and its glucose transport activity in 3T3-LI 
adipocytes.” American Journal Physiology Endocrinology and Metabolism 289.4 
(2005):E643-E649. 
Yamamoto, Y., et al. "Development and prevention of advanced diabetic nephropathy in 
RAGE-overexpressing mice." The Journal of Clinical Investigation 108.2 (2001): 
261-268. 
Yang, C.; et al. “Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in 
the treatment of high-risk proliferative diabetic retinopathy.” Journal of Ocular 
Pharmacology and Therapeutics 29.6 (2013): 550-555. 
68  
Yang, J.; et al. “A randomized trial of bevacizumab, and anti-vascular endothelial growth 
factor antibody, for metastatic renal cancer.” The New England Journal of 
Medicine 349.5 (2003): 427-434. 
Yeh, P., et al. "Astaxanthin inhibits expression of retinal oxidative stress and 
inflammatory mediators in streptozotocin-induced diabetic rats." PloS one 11.1 
(2016): e0146438. 
Ye, Xiaofeng, et al. "ERK1/2 signaling pathway in the release of VEGF from Müller cells 
in diabetes ERK1/2 signaling pathway in diabetes." Investigative Ophthalmology 
& Visual Science 53.7 (2012): 3481-3489. 
Zhang, S.X., et al. "Pigment epithelium-derived factor downregulates vascular 
endothelial growth factor (VEGF) expression and inhibits VEGF–VEGF receptor 
2 binding in diabetic retinopathy." Journal of Molecular Endocrinology 37.1 
(2006): 1-12. 
Zhang, R., et al. "Near infrared light protects cardiomyocytes from hypoxia and 
reoxygenation injury by a nitric oxide dependent mechanism." Journal of 
Molecular and Cellular Cardiology 46.1 (2009): 4-14. 
Zhao, H. S., et al. "Effect of the regimen of Gaoshan Hongjingtian on the mechanism of 
poly (ADP-ribose) polymerase regulation of nuclear factor kappa B in the 
experimental diabetic retinopathy." Chinese Medical Journal 126.9 (2012): 1693- 
1699. 
 
Zheng, L., C. Szabó, and T. S. Kern. "Poly (ADP-ribose) polymerase is involved in the 
development of diabetic retinopathy via regulation of nuclear factor- 
κB." Diabetes 53.11 (2004): 2960-296. 
69  
Zivin, J.A., et al. “Effectiveness and safety of transcranial laser therapy for acute 
ischemic stroke” Stroke 40.4 (2009): 1359-1364. 
Zong, H. et al. “Hyperglycemia-induced pro-inflammatory responses by retinal Müller 
glia are regulated by the receptor for advanced glycation end-products (RAGE).” 
Diabetologia 53.12 (2010):2656-2666. 
